https://crcwarriors.org/ 2026-07-29 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-07-29 daily 0.9 https://crcwarriors.org/medicamentos 2026-07-29 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-07-29 daily 0.8 https://crcwarriors.org/noticias 2026-07-29 daily 0.8 https://crcwarriors.org/combinaciones 2026-07-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-07-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-07-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-07-01 monthly 0.7 https://crcwarriors.org/contacto 2026-07-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-07-01 monthly 0.6 https://crcwarriors.org/colabora 2026-07-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT07294690/el-efecto-del-entrenamiento-preoperatorio-con-realidad-virtual-sobre-la-ansiedad-la-preparacion-para-la-cirugia-y-el-proceso-de-recuperacion-de-los-pacientes-sometidos-a-cirugia-de-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07294690/the-effect-of-preoperative-training-with-virtual-reality-on-anxiety-readiness-for-surgery-and-recovery-process-of-patients-in-colorectal-cancer-surgery 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406633/kqb198-en-combinacion-con-imatinib-en-participantes-con-gist-avanzado-metastasico-en-primera-linea-de-tratamiento 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406633/kqb198-in-combination-with-imatinib-in-participants-with-advanced-metastatic-gist-in-1st-line-setting-synergist-1st-line 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07236983/biodiversidad-de-la-microbiota-intestinal-en-pacientes-con-tumores-solidos-tratados-con-inhibidores-de-puntos-de-control-inmunitario-icpi-un-estudio-prospectivo-monocentrico-para-identificar-las 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07236983/gut-microbiota-gm-biodiversity-in-patients-with-solid-tumors-treated-with-immune-checkpoint-inhibitors-icis-a-monocenter-prospective-study-to-identify-the-interactions-between-gm-and-icis 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04443543/un-estudio-de-cohorte-prospectivo-con-diseno-adaptativo-sobre-la-estrategia-de-observacion-y-espera-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04443543/an-adaptive-design-prospective-cohort-study-of-watch-and-wait-strategy-in-patients-with-locally-advanced-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06337552/intervencion-con-alimentos-altamente-fermentados-en-pacientes-con-cancer-colorrectal-localmente-avanzado-el-estudio-feed 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06337552/high-fermented-food-intervention-among-locally-advanced-rectal-cancer-patients-the-feed-trial 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406594/cambios-en-el-microbioma-intestinal-durante-la-terapia-con-abemaciclib-en-el-cancer-de-mama 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406594/gut-microbiome-changes-during-abemaciclib-therapy-in-breast-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05484024/radioterapia-de-corta-duracion-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05484024/short-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07297030/sib-rt-combinado-con-capox-y-un-inhibidor-de-pd-1-para-el-cancer-colorrectal-de-alto-riesgo 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07297030/sib-rt-combined-with-capox-and-pd-1-for-high-risk-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06368141/quimioterapia-neoadyuvante-combinada-con-terapia-secuencial-con-inhibidores-de-puntos-de-control-inmunitario-ici-en-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06368141/neoadjuvant-chemotherapy-plus-sequential-immune-checkpoint-inhibitor-ici-therapy-in-locally-advanced-colon-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02919644/vacunacion-con-celulas-dendriticas-autologas-cargadas-con-homogenado-tumoral-autologo-tras-la-reseccion-curativa-del-cancer-colorrectal-en-estadio-iv 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02919644/vaccination-with-autologous-dendritic-cells-loaded-with-autologous-tumour-homogenate-after-curative-resection-for-stage-iv-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284992/scrt-frente-a-lcrt-seguido-de-un-inhibidor-de-pd-l1-mas-capeox-como-terapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-larc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284992/scrt-vs-lcrt-followed-by-pd-l1-inhibitor-plus-capeox-as-tnt-in-patients-with-larc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/irinotecano-nanoliposomal-oxaliplatino-mas-capecitabina-como-terapia-de-conversion-en-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/nanoliposomal-irinotecan-oxaliplatin-plus-capecitabine-as-conversion-therapy-of-locally-advanced-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503639/ensayo-clinico-umbrella-de-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503639/umbrella-trial-of-neoadjuvant-therapy-for-locally-advanced-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07505472/comparacion-de-la-eficacia-y-la-seguridad-de-un-ciclo-corto-de-radioterapia-seguido-de-quimioterapia-con-capeox-mas-toripalimab-con-o-sin-surufatinib-concomitante-en-la-terapia-neoadyuvante-para-el 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07505472/efficacy-and-safety-comparison-of-short-course-radiotherapy-followed-by-capeox-chemotherapy-plus-toripalimab-with-or-without-concurrent-surufatinib-in-neoadjuvant-therapy-for-mid-to-low-localized 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07509424/radioterapia-neoadyuvante-de-corta-duracion-seguida-de-una-combinacion-de-disitamab-vedotina-sintilimab-y-capecitabina-en-el-cancer-colorrectal-localmente-avanzado-con-expresion-de-her2 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509424/neoadjuvant-short-course-radiotherapy-followed-by-a-combination-of-disitamab-vedotin-sintilimab-and-capecitabine-in-locally-advanced-her2-expressing-rectal-cance 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06055439/un-estudio-de-fase-1-2-para-evaluar-chm-2101-una-terapia-celular-t-con-receptor-quimerico-de-antigeno-17-car-autologa 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/a-phase-1-2-study-to-evaluate-chm-2101-an-autologous-cadherin-17-chimeric-antigen-receptor-car-t-cell-therapy 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07622771/radioterapia-neoadyuvante-combinada-con-nalirifox-y-adebrelimab-en-cancer-colorrectal-localmente-avanzado-pmmr-mss-un-ensayo-clinico-prospectivo-aleatorizado-de-fase-ii 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622771/neoadjuvant-radiotherapy-combined-with-nalirifox-and-adebrelimab-in-pmmr-mss-locally-advanced-rectal-cancer-a-prospective-randomized-phase-ii-clinical-trial 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02008656/ensayo-que-evalua-la-supervivencia-libre-de-enfermedad-a-3-anos-en-pacientes-con-cancer-colorrectal-localmente-avanzado-tratados-con-quimiorradiacion-mas-quimioterapia-de-induccion-o-consolidacion-y 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02008656/trial-evaluating-3-year-disease-free-survival-in-patients-with-locally-advanced-rectal-cancer-treated-with-chemoradiation-plus-induction-or-consolidation-chemotherapy-and-total-mesorectal-excision-or 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06923345/radioterapia-de-larga-duracion-modificada-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-pacientes-con-cancer-colorrectal-localmente-avanzado-de-riesgo-alto-y-con-msi-pmmr-estudio-modifi-rc-i 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/modified-long-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-mss-pmmr-high-risk-mid-low-larc-modifi-rc-i 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03179540/manejo-no-quirurgico-del-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03179540/non-operative-management-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07636382/ablacion-del-plexo-celiaco-para-el-dolor-mediante-radioterapia-estereotactica-sin-necesidad-de-simulacion-en-pacientes-con-dolor-celiaco-relacionado-con-el-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07636382/simulation-free-celiac-plexus-pain-ablation-using-stereotactic-body-radiotherapy-in-patients-with-cancer-related-celiac-pain 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/quimioterapia-neoadyuvante-con-capox-con-o-sin-pucotenlimab-mas-radioterapia-selectiva-para-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/neoadjuvant-capox-with-or-without-pucotenlimab-plus-selective-radiotherapy-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06098560/el-adn-tumoral-circulante-ctdna-como-biomarcador-predictivo-para-la-inmunoterapia-en-pacientes-con-cancer-colorrectal-avanzado-o-localmente-avanzado-con-dmmr-msi-h 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06098560/circulating-tumor-dna-ctdna-as-a-predictive-biomarker-for-immunotherapy-in-advanced-or-locally-advanced-dmmr-msi-h-colorectal-patients 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05571644/tratamiento-neoadyuvante-con-mfolfoxiri-mas-cadonilimab-ak104-frente-a-mfolfox6-en-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05571644/neoadjuvant-treatment-with-mfolfoxiri-plus-cadonilimab-ak104-versus-mfolfox6-in-locally-advanced-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05973487/un-estudio-basket-de-terapias-celulares-autologas-de-tcr-t-personalizadas-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-irresecables 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05973487/a-basket-study-of-customized-autologous-tcr-t-cell-therapies-in-patients-with-locally-advanced-unresectable-or-metastatic-solid-tumors 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07644286/un-estudio-de-fase-ii-de-pirfenidona-mas-un-inhibidor-de-pd-1-con-o-sin-radioterapia-hipofraccionada-para-el-cancer-colorrectal-refractario-pmmr-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07644286/a-phase-ii-study-of-pirfenidone-plus-pd-1-inhibitor-with-or-without-hypofractionated-radiotherapy-for-refractory-pmmr-mss-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05723562/un-estudio-de-dostarlimab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-dmmr-msi-h-no-tratados-previamente 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05723562/a-study-of-dostarlimab-in-untreated-dmmr-msi-h-locally-advanced-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07038122/reduccion-del-margen-de-reseccion-tras-la-terapia-neoadyuvante-en-canceres-localmente-avanzados-de-la-union-rectosigmoidea-y-del-recto-superior 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07038122/reducing-the-resection-range-after-neoadjuvant-therapy-for-locally-advanced-upper-rectal-and-rectosigmoid-junction-cancers 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06276686/ejercicio-para-mejorar-la-eficacia-de-la-quimiorradioterapia-prolongada-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/exercise-for-improving-long-course-chemoradiotherapy-efficacy-in-people-with-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04928807/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-y-camrelizumab-en-el-cancer-colorrectal-localmente-avanzado-union 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04928807/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-and-camrelizumab-in-locally-advanced-rectal-cancer-union 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05507112/time-en-inmunoterapia-combinada-con-quimiorradioterapia-neoadyuvante-en-el-cancer-de-recto 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05507112/time-in-immunotherapy-combined-with-ncrt-for-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03981497/ablacion-por-microondas-para-el-tratamiento-de-tumores-renales-pequenos-y-neoplasias-hepaticas-primarias-y-secundarias 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03981497/microwave-ablation-for-treatment-of-small-renal-tumors-and-primary-and-secondary-liver-neoplasms 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07020468/terapia-neoadyuvante-nalirifox-para-el-cancer-colorrectal-localmente-avanzado-y-el-cancer-del-recto-superior 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07020468/neoadjuvant-therapy-nalirifox-for-locally-advanced-colon-and-upper-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05601505/estrategia-de-tratamiento-neoadyuvante-guiada-por-el-adn-tumoral-circulante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/circulating-tumor-dna-guided-neoadjuvant-treatment-strategy-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663775/mesalazina-como-tratamiento-profilactico-para-prevenir-la-colitis-tras-el-tratamiento-con-ipilimumab-nivolumab-ipi-nivo 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663775/prophylactic-mesalamine-to-prevent-colitis-following-treatment-with-ipilimumab-nivolumab-ipi-nivo 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-en-el-tratamiento-de-pacientes-jovenes-con-gliomas-de-alto-grado-recurrentes-progresivos-o-refractarios-gliomas-intrinsecos-del-tronco-encefalico-difusos-tumores-cerebrales-hipermutados 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-in-treating-younger-patients-with-recurrent-progressive-or-refractory-high-grade-gliomas-diffuse-intrinsic-pontine-gliomas-hypermutated-brain-tumors-ependymoma-or-medulloblastoma 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05585814/capeox-en-combinacion-con-bevacizumab-mas-un-anticuerpo-anti-pd1-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-estabilidad-microsatelital 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05585814/capeox-combined-with-bevacizumab-plus-anti-pd1-antibody-as-neoadjuvant-therapy-for-microsatellite-stable-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154316/ensayo-clinico-fase-ii-aleatorizado-y-controlado-que-compara-la-quimiorradioterapia-neoadyuvante-lcrt-frente-a-la-radioterapia-neoadyuvante-de-corta-duracion-scrt-combinada-con-capox-un-inhibidor-de 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154316/phase-ii-rct-of-lcrt-vs-scrt-capox-pd-1i-cox-2i-in-mss-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomica-para-predecir-la-respuesta-al-tratamiento-y-las-toxicidades-en-el-cancer-de-recto 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomics-to-predict-treatment-response-and-toxicities-in-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/eficacia-y-seguridad-de-la-terapia-neoadyuvante-convencional-frente-a-la-terapia-neoadyuvante-total-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/efficacy-and-safety-of-conventional-neoadjuvant-therapy-versus-total-neoadjuvant-therapy-in-older-patients-with-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/una-intervencion-informativa-y-de-apoyo-para-pacientes-con-cancer-de-recto-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/an-informational-and-supportive-care-intervention-for-patients-with-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/adg126-y-pembrolizumab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/neoadjuvant-adg126-and-pembrolizumab-in-locally-advanced-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/quimioterapia-neoadyuvante-anticuerpo-anti-pd-1-y-sitagliptina-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/neoadjuvant-chemotherapy-anti-pd-1-antibody-and-sitagliptin-for-locally-advanced-pmmr-crc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549906/iparomlimab-tuvonralimab-neoadyuvante-mas-capeox-frente-a-iparomlimab-tuvonralimab-mas-capeox-y-propranolol-para-el-cancer-colorrectal-localmente-avanzado-pmmr-un-estudio-prospectivo-unicentrico-y 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/neoadjuvant-iparomlimab-tuvonralimab-plus-capeox-versus-iparomlimab-tuvonralimab-plus-capeox-and-propranolol-for-locally-advanced-pmmr-colon-cancer-a-prospective-single-center-multi-cohort-study 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06698757/diferentes-ciclos-de-sintilimab-neoadyuvante-preoperatorio-en-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-de-errores-de-emparejamiento-alta-inestabilidad-de-microsatelites 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698757/different-cycles-of-preoperative-neoadjuvant-sintilimab-in-mismatch-repair-deficient-microsatellite-instability-high-locally-advanced-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03659448/eficacia-de-sgm-101-para-la-delimitacion-del-tumor-primario-y-de-las-recurrencias-tumorales-y-metastasis-en-pacientes-sometidos-a-cirugia-por-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03659448/performance-of-sgm-101-for-the-delineation-of-primary-and-recurrent-tumor-and-metastases-in-patients-undergoing-surgery-for-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06312982/una-serie-de-casos-de-quimiorradioterapia-neoadyuvante-combinada-con-inmunoterapia-para-el-cancer-de-recto-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06312982/a-series-of-neoadjuvant-chemoradiotherapy-combined-with-immunotherapy-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/quimiorradiacion-neoadyuvante-con-nal-iri-y-capecitabina-guiada-por-el-estado-de-ugt1a1-en-pacientes-con-cancer-de-recto 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/neoadjuvant-chemoradiation-with-nal-iri-and-capecitabine-guided-by-ugt1a1-status-in-patients-with-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07372300/electrohipertermia-modulada-en-combinacion-con-terapia-multimodal-para-el-cancer-de-recto-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07372300/modulated-electro-hyperthermia-in-combination-with-multimodal-therapy-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-para-el-cancer-colorrectal-avanzado-msi-h-dmmr-que-no-responde-al-bloqueo-de-pd-1-pd-l1 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-for-pd-1-pd-l1-blockade-refractory-msi-h-dmmr-advanced-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07132008/quimioterapia-neoadyuvante-con-capox-mas-tislelizumab-frente-a-capox-en-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-mss 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07132008/neoadjuvant-capox-plus-tislelizumab-vs-capox-in-mss-high-risk-locally-advanced-colon-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07183124/modelado-tridimensional-para-la-deteccion-del-cancer-colorrectal-localmente-avanzado-con-margenes-de-reseccion-circunferencial-positivos 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07183124/3d-modeling-for-detecting-locally-advanced-rectal-cancer-with-positive-circumferential-resection-margin 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03466424/radioterapia-de-corta-duracion-5-x-6-gy-7-gy-8-gy-seguida-de-quimioterapia-neoadyuvante-para-el-cancer-de-recto-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/short-course-radiotherapy-5x6gy-7gy-8gy-followed-by-neo-adjuvant-chemotherapy-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05877573/toripalimab-en-combinacion-con-quimiorradioterapia-neoadyuvante-como-tratamiento-de-primera-linea-para-el-cancer-de-recto-localmente-avanzado-de-alto-riesgo-y-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05877573/toripalimab-combined-with-neoadjuvant-chemoradiotherapy-as-first-line-treatment-for-locally-advanced-high-risk-mss-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244537/estudio-sobre-la-seguridad-y-la-eficacia-de-la-tecnica-mr-linac-en-pacientes-con-cancer-colorrectal-localmente-avanzado-irresecable 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244537/study-on-the-safety-and-efficacy-of-mr-linac-technique-in-patients-with-unresectable-locally-advanced-colon-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645301/bgt007-tratamiento-para-tumores-gastrointestinales-recurrentes-o-refractarios 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06645301/bgt007-treatment-for-recurrent-refractory-gastrointestinal-malignancies 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06017583/quimioterapia-neoadyuvante-con-inhibidores-de-pd-1-combinada-con-sib-imrt-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06017583/neoadjuvant-chemotherapy-with-pd-1-inhibitors-combined-with-sib-imrt-in-the-treatment-of-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/regimen-terapeutico-sandwich-modificado-para-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/modified-sandwich-therapeutic-regimen-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06976710/ensayo-priority-connect-2 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06976710/priority-connect-2-trial 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07381400/quimioterapia-neoadyuvante-con-mfolfox6-combinada-con-terapia-anti-pd-1-en-cancer-colorrectal-localmente-avanzado-mss-pmmr-estudio-firm02 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381400/neoadjuvant-mfolfox6-chemotherapy-combined-with-anti-pd-1-therapy-in-mss-pmmr-locally-advanced-rectal-cancer-firm02-study 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06369259/estudio-de-fase-2-abierto-con-avutometinib-inhibidor-de-raf-mek-en-combinacion-con-defactinib-inhibidor-de-fak-y-cetuximab-en-pacientes-con-cancer-colorrectal-avanzado-irresecable-y-resistente-a-los 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combination-with-defactinib-fak-inhibitor-and-cetuximab-in-patients-with-unresectable-anti-egfr-refractory-advanced-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07394192/radioterapia-de-corta-duracion-con-preservacion-de-los-ganglios-linfaticos-que-drenan-el-tumor-seguida-de-inhibidores-de-pd-1-en-el-cancer-de-recto-en-estadio-ii-iii-con-pmmr-mss 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07394192/short-course-radiotherapy-with-tumor-draining-lymph-node-preservation-followed-by-pd-1-inhibitors-in-pmmr-mss-stage-ii-iii-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06753136/electroquimioterapia-ect-en-pacientes-con-tumores-viscerales-primarios-y-o-localizaciones-viscerales-secundarias-de-cualquier-histotipo 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06753136/electrochemotherapy-ect-in-patients-with-primary-visceral-tumors-and-or-secondary-visceral-localizations-of-any-histotype 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/inhibidores-de-los-puntos-de-control-inmunitario-quimioterapia-frente-a-quimioterapia-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/immune-checkpoint-inhibitors-chemotherapy-versus-chemotherapy-in-the-neoadjuvant-treatment-of-locally-advanced-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06765616/inyeccion-de-adebrelimab-pd-l1-combinada-con-radioterapia-de-corta-duracion-y-quimioterapia-para-la-terapia-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06765616/adebrelimab-injection-pd-l1-combined-with-short-course-radiotherapy-and-chemotherapy-for-neoadjuvant-therapy-of-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06879899/vigilancia-guiada-por-la-enfermedad-residual-minima-en-el-cancer-de-recto-localmente-avanzado-de-localizacion-media-o-baja-surveillance-iii 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06879899/mrd-guided-surveillance-in-locally-advanced-mid-low-rectal-cancer-surveillance-iii 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580339/combinacion-de-dcsz11-con-radioterapia-y-quimioterapia-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580339/combining-dcsz11-with-radiation-and-chemotherapy-as-neoadjuvant-treatment-for-pmmr-locally-advanced-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07404228/estudio-multidimensional-disenado-para-desarrollar-un-marco-metodologico-basado-en-datos-de-resonancia-magnetica-rm-con-el-fin-de-predecir-la-respuesta-patologica-completa-pcr-en-pacientes-con-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07404228/multidimensional-study-designed-to-develop-a-methodological-framework-based-on-mri-data-to-predict-pathological-complete-response-pcr-in-patients-with-locally-advanced-rectal-cancer-after-neoadjuvant 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07090304/ensayo-chino-sobre-la-deteccion-del-cancer-colorrectal-2-c-cost2 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07090304/china-colorectal-cancer-screening-trial-2-c-cost2 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/radioterapia-preoperatoria-adaptativa-concomitante-con-quimioterapia-para-el-adenocarcinoma-rectal-ensayo-adaptativo-de-cancer-rectal-02 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/preoperative-adaptive-radiotherapy-concomitant-to-chemotherapy-for-rectal-adenocarcinoma-adaptive-rectal-cancer-trial-02 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05646511/tnt-de-quimiorradioterapia-qrt-capox-frente-a-qrt-capoxiri-para-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05646511/tnt-of-scrt-capox-vs-scrt-capoxiri-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04223102/microbioma-y-cancer-de-recto 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04223102/microbiome-and-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03391843/quimioterapia-neoadyuvante-combinada-con-cetuximab-para-el-cancer-colorrectal-localmente-avanzado-con-egfr-de-tipo-salvaje 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03391843/neoadjuvant-chemotherapy-combined-with-cetuximab-for-egfr-wild-type-locally-advanced-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05136326/quimiorradioterapia-preoperatoria-con-capecitabina-y-temozolomida-en-cancer-colorrectal-localmente-avanzado-con-expresion-de-mgmt-silenciada-y-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05136326/preoperative-chemoradiotherapy-with-capecitabine-and-temozolomide-in-mgmt-silenced-mss-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06888843/estudio-para-evaluar-el-uso-de-capecitabina-en-monoterapia-y-en-combinacion-con-oxaliplatino-en-pacientes-ancianos-como-quimioterapia-adyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06888843/study-to-evaluate-the-use-of-capecitabine-in-monotherapy-and-in-combination-with-oxaliplatin-in-elderly-patients-as-adjuvant-chemotherapy-for-locally-advanced-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05610163/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-el-irinotecan-al-tratamiento-de-quimioterapia-estandar-folfox-tras-la-radioterapia-prolongada-en-pacientes-con-cancer-de-recto-en-estadio-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05610163/testing-the-addition-of-an-anti-cancer-drug-irinotecan-to-the-standard-chemotherapy-treatment-folfox-after-long-course-radiation-therapy-for-advanced-stage-rectal-cancers-to-improve-the-rate-of 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07413146/quimioterapia-neoadyuvante-con-capeox-frente-a-cirugia-inicial-en-cancer-colorrectal-localmente-avanzado-con-niveles-elevados-de-cea-un-ensayo-clinico-aleatorizado-abierto-y-de-un-solo-centro 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07413146/neoadjuvant-capeox-versus-upfront-surgery-for-locally-advanced-colon-cancer-with-elevated-cea-a-single-center-open-label-randomized-controlled-trial 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/radioterapia-de-curso-corto-con-preservacion-de-los-ganglios-junto-con-capox-y-sintilimab-para-el-cancer-colorrectal-localmente-avanzado-mss-un-estudio-aleatorizado-prospectivo-y-multicentrico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/node-sparing-short-course-radiation-with-capox-and-sintilimab-for-mss-locally-advanced-colon-cancer-a-randomized-prospective-multicenter-study 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06207981/estudio-de-fase-iii-que-evalua-la-quimioterapia-de-induccion-seguida-de-quimiorradioterapia-en-comparacion-con-la-quimiorradioterapia-estandar-para-el-carcinoma-de-celulas-escamosas-localmente 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06207981/phase-iii-study-evaluating-induction-chemotherapy-followed-by-chemoradiotherapy-compared-to-standard-chemoradiotherapy-for-locally-advanced-scca 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853769/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/deteccion-del-cancer-colorrectal-en-pacientes-de-edad-avanzada-ensayo-de-deteccion-plco 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/screening-for-colorectal-cancer-in-older-patients-plco-screening-trial 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-radioterapia-eliminacion-de-la-terapia-tnt-y-terapia-neoadyuvante 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/treatment-of-low-locally-advanced-rectal-cancer-with-radiotherapy-removal-tnt-plus-neoadjuvant-therapy 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07407647/dhea-vaginal-para-mejorar-la-salud-vaginal-despues-de-la-radioterapia-en-mujeres-con-cancer-ginecologico-anal-o-de-recto 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07407647/vaginal-dhea-to-improve-vaginal-health-after-radiation-for-women-with-gynecologic-anal-or-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07425054/quimiocirradiacion-adaptada-a-la-respuesta-del-adn-tumoral-circulante-de-vph-tratamiento-con-retifanlimab-en-cancer-anal-en-estadio-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07425054/cthpvdna-response-adapted-chemoradiation-retifanlimab-treatment-in-locally-advanced-anal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-en-combinacion-con-adbelizumab-y-bp102-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-combined-with-adbelizumab-and-bp102-in-the-treatment-of-advanced-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05984485/la-eficacia-de-la-cirugia-primaria-de-reseccion-total-del-mesorrecto-tme-frente-a-la-quimioterapia-neoadyuvante-combinada-con-la-cirugia-tme-en-el-cancer-colorrectal-localmente-avanzado-de-bajo-riesgo 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/the-efficacy-of-primary-total-mesorectal-excision-tme-surgery-versus-neoadjuvant-chemotherapy-combined-with-tme-surgery-in-low-risk-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998758/megestrol-acetato-para-mejorar-la-perdida-de-peso-relacionada-con-la-quimioterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998758/megestrol-acetate-in-improving-neoadjuvant-chemotherapy-related-weight-loss-in-locally-advanced-crc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/estudio-de-no-inferioridad-de-la-quimioterapia-preoperatoria-sin-irradiacion-pelvica-para-el-cancer-de-recto 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/non-inferiority-study-of-preoperative-chemotherapy-without-pelvic-irradiation-for-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-frente-a-capox-como-terapia-neoadyuvante-total-para-cancer-de-recto-pmmr 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-vs-capox-as-total-neoadjuvant-therapy-for-pmmr-low-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06424522/un-programa-de-manejo-intestinal-enema-rectal-retrogrado-para-el-tratamiento-del-sindrome-de-reseccion-anterior-baja-en-pacientes-con-cancer-de-recto 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06424522/a-bowel-management-program-retrograde-rectal-enema-for-the-treatment-of-low-anterior-resection-syndrome-in-rectal-cancer-patients 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07080411/la-eficacia-de-la-radioterapia-adaptativa-en-linea-guiada-por-resonancia-magnetica-para-el-cancer-de-recto-localmente-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07080411/the-efficacy-of-mr-guided-online-adaptive-radiotherapy-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06380101/evaluacion-de-un-alimento-medico-con-restriccion-de-aminoacidos-no-esenciales-neaar-en-combinacion-con-terapia-neoadyuvante-total-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06380101/evaluating-a-nonessential-amino-acid-restriction-neaar-medical-food-with-total-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-larc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06596343/evaluacion-de-los-beneficios-de-la-medicina-tradicional-china-personalizada-en-el-tratamiento-postoperatorio-del-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06596343/evaluating-the-benefits-of-personalized-traditional-chinese-medicine-in-postoperative-treatment-for-locally-advanced-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05673772/radioterapia-secuencial-preoperatoria-de-corta-duracion-y-folfox-para-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05673772/preoperative-sequential-short-course-radiation-therapy-and-folfox-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843434/un-estudio-de-botensilimab-y-balstilimab-para-el-adenocarcinoma-rectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06843434/a-study-of-botensilimab-and-balstilimab-for-rectal-adenocarcinoma 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06443671/fruquintinib-neoadyuvante-mas-tislelizumab-en-combinacion-con-mcapeox-frente-a-capeox-para-el-cancer-colorrectal-localmente-avanzado-de-pmmr-mss-intermedio-alto 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06443671/neoadjuvant-fruquintinib-plus-tislelizumab-combined-with-mcapeox-versus-capeox-for-mid-high-pmmr-mss-locally-advanced-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05450029/quimiorradioterapia-neoadyuvante-mas-sintilimab-para-el-cancer-colorrectal-localmente-avanzado-de-riesgo-intermedio-alto-segun-el-indice-de-inmunidad 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05450029/neoadjuvant-chemoradiotherapy-plus-sintilimab-for-intermediate-high-immunoscore-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06640049/un-estudio-de-dostarlimab-en-participantes-con-cancer-colorrectal-localmente-avanzado-no-tratado-en-china 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06640049/a-study-of-dostarlimab-in-participants-with-untreated-locally-advanced-rectal-cancer-in-china 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06911684/radioterapia-mas-iparolimab-y-tuvonalimab-ql1706-regorafenib-y-capox-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06911684/radiotherapy-plus-iparomlimab-and-tuvonralimab-ql1706-regorafenib-and-capox-as-neoadjuvant-therapy-for-pmmr-mss-larc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02113384/cancer-colorrectal-localmente-avanzado-celulas-tumorales-exfoliadas-del-peritoneo 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02113384/locally-advanced-rectal-cancer-exfoliated-peritoneal-tumor-cells 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05563922/estrategia-de-preservacion-organica-mediante-quimiorradioterapia-neoadyuvante-total-para-el-carcinoma-rectal-bajo 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05563922/organ-preservation-strategy-of-total-neoadjuvant-chemoradiotherapy-for-low-rectal-carcinoma 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03921684/ensayo-clinico-de-nivolumab-en-combinacion-con-folfox-tras-quimiorradioterapia-en-pacientes-con-cancer-de-recto 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03921684/trial-of-nivolumab-with-folfox-after-chemoradiation-in-rectal-cancer-patients 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07239466/un-estudio-piloto-que-evalua-la-suplementacion-con-hidroxibutirato-en-combinacion-con-radioterapia-de-corta-duracion-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-con-capeox-en 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07239466/a-pilot-study-evaluating-hydroxybutyrate-supplementation-concomitant-to-short-course-radiotherapy-followed-by-immunotherapy-combined-with-capeox-neoadjuvant-therapy-in-patients-with-locally-advanced 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06441565/fruquintinib-solo-o-en-combinacion-con-hai-folfox-para-el-cancer-colorrectal-refractario 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06441565/fruquintinib-with-or-without-hai-folfox-for-refractory-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965166/tomografia-computarizada-con-detector-de-fotones-de-conteo-y-contraste-pcd-ct-para-la-estadificacion-local-del-cancer-de-recto 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965166/contrast-enhanced-photon-counting-detector-ct-pcd-ct-for-the-local-staging-of-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07279077/radioterapia-de-baja-dosis-con-conservacion-de-los-ganglios-linfaticos-administrada-de-forma-concurrente-con-quimioterapia-e-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07279077/node-sparing-low-dose-radiotherapy-concurrent-with-chemotherapy-and-pd-1-inhibitor-in-pmmr-mss-high-risk-locally-advanced-colon-cancer-a-prospective-single-arm-phase-ii-trial 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05722288/alimentacion-con-horarios-restringidos-frente-a-asesoramiento-nutricional-para-la-reduccion-de-los-efectos-secundarios-del-tratamiento-con-radioterapia-o-quimiorradioterapia-en-pacientes-con-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05722288/time-restricted-eating-versus-nutritional-counseling-for-the-reduction-of-radiation-or-chemoradiation-tx-side-effects-in-patients-with-prostate-cervical-or-rectal-cancers 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06516445/radioterapia-de-corta-duracion-seguida-de-camrelizumab-en-combinacion-con-fluzoparib-y-quimioterapia-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06516445/scrt-followed-by-camrelizumab-combined-with-fluzoparib-and-chemotherapy-as-neoadjuvant-therapy-for-larc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07166263/seguridad-y-eficacia-de-nk510-en-el-tratamiento-del-cancer-gastrico-y-del-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07166263/safety-and-efficacy-of-nk510-to-treat-gastric-cancer-and-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06550453/seguridad-y-eficacia-de-pembrolizumab-en-combinacion-con-bevacizumab-y-capecitabina-mas-oxaliplatino-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado-con-mutacion-en-ras-braf 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06550453/safety-and-efficacy-of-pembrolizumab-in-combination-with-bevacizumab-capeox-in-the-neoadjuvant-treatment-of-ras-mutated-braf-wild-type-microsatellite-stabilized-locally-advanced-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04677413/radioterapia-ultrafraccionada-para-el-cancer-de-recto 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04677413/ultra-fractionated-radiotherapy-for-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04215731/mfolfoxiri-neoadyuvante-mas-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-de-alto-riesgo 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/neoadjuvant-mfolfoxiri-plus-bevacizumab-in-patients-with-high-risk-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965531/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-quimioterapia-con-tas-102-mas-radioterapia-neoadyuvante 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965531/treating-locally-advanced-rectal-cancer-with-tas-102-chemotherapy-plus-neoadjuvant-radiotherapy 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07594925/radioterapia-de-corta-duracion-seguida-de-inmunoterapia-combinada-con-quimioterapia-para-el-cancer-colorrectal-localmente-avanzado-con-estabilidad-de-microsatelites-un-ensayo-clinico-prospectivo 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07594925/short-course-radiotherapy-followed-by-immunotherapy-combined-with-chemotherapy-for-microsatellite-stable-locally-advanced-rectal-cancer-a-prospective-randomized-controlled-phase-ii-clinical-trial 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06577194/un-estudio-de-un-solo-centro-de-un-solo-brazo-sobre-radioterapia-neoadyuvante-de-curso-corto-con-il-2-seguida-de-inmunoterapia-secuencial-con-capox-combinada-con-un-anticuerpo-anti-pd-1-e-il-2-para 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06577194/neoadjuvant-short-course-radiotherapy-followed-by-capox-plus-pd-1-antibody-and-il-2-in-locally-advanced-rectal-cancer-pride01 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06254521/los-efectos-del-tratamiento-neoadyuvante-con-tislelizumab-en-combinacion-con-quimioterapia-en-el-cancer-colorrectal-localmente-avanzado-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06254521/the-effects-of-neoadjuvant-tislelizumab-combined-with-chemotherapy-in-locally-advanced-mss-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/estudio-del-algoritmo-pagoda-para-ajustar-las-dosis-de-quimioterapia-y-prevenir-retrasos-no-previstos-en-el-tratamiento 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/studying-the-pagoda-algorithm-for-chemotherapy-dose-changes-to-prevent-unplanned-treatment-delays 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluacion-del-contacto-con-rayos-x-y-la-braquiterapia-para-la-preservacion-del-recto-en-el-adenocarcinoma-rectal-de-estadio-intermedio 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluation-contact-x-ray-brachytherapy-for-rectal-preservation-in-intermediate-substage-rectal-adenocarcinoma 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05969847/preservacion-de-organos-tras-la-terapia-neoadyuvante-total-basada-en-enverolimab-para-el-cancer-colorrectal-localmente-avanzado-en-estadio-muy-temprano 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05969847/organ-preservation-following-enverolimab-based-total-neoadjuvant-therapy-for-locally-advanced-very-low-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-mas-inhibidor-de-pd-1-frente-a-mfolfox6-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-plus-pd-1-inhibitor-vs-mfolfox6-as-neoadjuvant-therapy-for-locally-advanced-colon-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-inmunoterapia-dual-anti-pd-1-ctla-4-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-anti-pd-1-ctla-4-dual-immunotherapy-for-larc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05605353/aprovechando-el-potencial-del-microbioma-intestinal-y-sus-metabolitos-en-el-cancer-pelvico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05605353/exploiting-the-gut-microbiota-and-its-metabolites-in-pelvic-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02843191/quimioterapia-de-consolidacion-para-el-cancer-de-recto-localmente-avanzado-ya-sea-de-localizacion-media-o-baja-tras-la-quimiorradioterapia-neoadyuvante-concurrente 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02843191/consolidation-chemotherapy-for-locally-advanced-mid-or-low-rectal-cancer-after-neoadjuvant-concurrent-chemoradiotherapy 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04495088/quimioterapia-folfox-preoperatoria-frente-a-quimioterapia-postoperatoria-adaptada-al-riesgo-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04495088/preoperative-folfox-versus-postoperative-risk-adapted-chemotherapy-in-patients-with-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783491/eficacia-del-uso-de-la-quimioterapia-neoadyuvante-con-o-sin-hipertermia-intraabdominal-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783491/efficacy-of-the-use-of-neoadjuvant-with-without-hyperthermic-intraperitoneal-chemotherapy-in-the-treatment-of-locally-advanced-colon-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07478731/tratamiento-neoadyuvante-con-shr-1701-mas-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07478731/neoadjuvant-shr-1701-plus-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03516708/se-anade-epacadostat-incb024360-a-la-quimiorradiacion-preoperatoria-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03516708/epacadostat-incb024360-added-to-preoperative-chemoradiation-in-patients-with-locally-advanced-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07472868/quimioterapia-neoadyuvante-con-folfoxiri-y-quimiorradioterapia-frente-a-quimioterapia-neoadyuvante-con-capox-folfox-y-quimiorradioterapia-seguida-de-cirugia-o-una-estrategia-de-observacion-activa-en 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07472868/neoadjuvant-folfoxiri-and-chemoradiotherapy-versus-neoadjuvant-capox-folfox-and-chemoradiotherapy-followed-by-surgery-or-a-watch-and-wait-approach-in-high-risk-locally-advanced-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014944/radioterapia-de-corta-duracion-combinada-con-furoquintinib-y-anticuerpo-monoclonal-anti-pd-1 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014944/short-course-radiotherapy-combined-with-furoquintinib-and-pd-1-monoclonal-antibody 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06929481/deteccion-mediante-un-analisis-de-sangre-para-identificar-el-adn-con-el-fin-de-abordar-las-desigualdades-en-el-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06929481/screening-with-a-dna-blood-test-to-address-colorectal-cancer-inequities 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06972498/estudio-multicentrico-prospectivo-ivosimab-quimioterapia-como-tratamiento-neoadyuvante-para-metastasis-hepaticas-de-crc-pmmr-mss-resecable 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06972498/a-prospective-multicenter-study-ivosimab-chemotherapy-as-neoadjuvant-for-resectable-pmmr-mss-crc-liver-mets 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-en-combinacion-con-shr2554-y-bp102-para-el-cmmr 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-combined-with-shr2554-and-bp102-for-mcrc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05636085/rendimiento-clinico-del-test-de-deteccion-de-cancer-colorrectal-de-mainz-biomed-para-el-cancer-colorrectal-y-el-adenoma-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05636085/clinical-performance-of-the-mainz-biomed-colorectal-cancer-screening-test-for-colorectal-cancer-and-advanced-adenoma 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-mas-un-inhibidor-de-puntos-de-control-en-combinacion-o-de-forma-secuencial-junto-con-tas-102-en-pacientes-con-cancer-colorrectal-que-han-progresado-tras-recibir-una-terapia-estandar-de 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-plus-checkpoint-inhibitor-combined-or-sequential-tas-102-in-colorectal-cancer-patients-who-progressed-on-second-line-standard-therapy-a-prospective-multi-cohort-single-centered-phase-ib 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07018869/evaluacion-de-si-un-sitio-web-educativo-denominado-current-together-after-cancer-ctac-mejora-la-atencion-de-seguimiento-para-los-supervivientes-de-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07018869/evaluating-whether-an-educational-website-called-current-together-after-cancer-ctac-improves-follow-up-care-for-colorectal-cancer-survivors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05694936/combinacion-de-valproato-sodico-con-el-tratamiento-estandar-con-anticuerpos-monoclonales-dirigidos-al-egfr-receptor-del-factor-de-crecimiento-epidermico-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05694936/combining-sodium-valproate-with-standard-of-care-egfr-epidermal-growth-factor-receptor-monoclonal-antibody-treatment-in-patients-with-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612007/hrx215-un-farmaco-inhibidor-de-mkk4-de-primera-generacion-para-el-tratamiento-de-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-despues-de-someterse-a-una-embolizacion-de-la-vena-porta 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612007/hrx215-a-first-generation-mkk4-inhibitor-drug-for-the-treatment-of-patients-with-colorectal-liver-metastasis-after-undergoing-a-portal-vein-embolization 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07494201/estudio-mimicc-en-pacientes-con-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07494201/mimicc-study-in-patients-with-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03776591/colecolectomia-derecha-abierta-versus-colecolectomia-minimamente-invasiva-laparoscopica-para-el-cancer-de-colon-derecho 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03776591/open-d3-right-hemicolectomy-compared-to-laparoscopic-cme-for-right-sided-colon-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06578559/estudio-de-fase-ii-de-encorafenib-mas-cetuximab-con-retratamiento-guiado-por-ctdna-en-pacientes-con-mcrc-con-mutacion-braf-v600e 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06578559/phase-ii-study-of-ctdna-guided-encorafenib-plus-cetuximab-retreatment-in-patients-braf-v600e-mutated-mcrc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06821048/estudio-de-la-terapia-car-t-dirigida-contra-el-cea-ptc13-en-el-tratamiento-de-tumores-solidos-malignos-avanzados-cea-positivos 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06821048/study-of-cea-targeting-car-t-ptc13-in-the-treatment-of-cea-positive-advanced-malignant-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/estudio-del-tratamiento-con-pembrolizumab-tras-la-administracion-de-cyad-101-con-acondicionamiento-previo-con-folfox-en-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/study-of-pembrolizumab-treatment-after-cyad-101-with-folfox-preconditioning-in-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/estudio-de-fase-iii-con-ivonescimab-o-bevacizumab-en-combinacion-con-folfox-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/phase-iii-study-of-ivonescimab-or-bevacizumab-combined-with-folfox-in-patients-with-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07178717/un-estudio-para-caracterizar-el-uso-de-encorafenib-mas-cetuximab-como-tratamiento-de-reintroduccion-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-braf-v600e-tras-una-terapia-previa-con 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07178717/a-study-to-characterize-encorafenib-plus-cetuximab-as-rechallenge-treatment-for-braf-v600e-mutant-metastatic-colorectal-cancer-patients-after-previous-therapy-with-braf-inhibitors-based-combinations 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07306390/distribucion-y-analisis-de-los-ganglios-linfaticos-metastasicos-en-pacientes-con-cancer-colorrectal-diamond 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07306390/distribution-and-analysis-of-metastatic-lymph-nodes-in-colorectal-cancer-patients-diamond 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503756/js212-terapias-combinadas-en-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503756/js212-combination-therapies-in-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07222800/symbiotic-gi-03-un-estudio-para-obtener-mas-informacion-sobre-el-farmaco-de-estudio-denominado-pf-08634404-en-combinacion-con-quimioterapia-en-participantes-adultos-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07222800/symbiotic-gi-03-a-study-to-learn-about-the-study-medicine-called-pf-08634404-in-combination-with-chemotherapy-in-adult-participants-with-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07226115/aprendizaje-predictivo-basado-en-el-empalme-para-la-evaluacion-individual-de-la-quimioterapia-en-el-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07226115/splicing-based-predictive-learning-for-individual-chemotherapy-evaluation-in-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07506109/un-estudio-de-fase-ii-de-sintilimab-en-combinacion-con-ipilimumab-n01-cetuximab-y-dabrafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-microsatelites-estables-y-mutacion-braf-v600e 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07506109/a-phase-ii-study-of-sintilimab-combined-with-ipilimumab-n01-cetuximab-and-dabrafenib-in-patients-with-microsatellite-stable-braf-v600e-mutated-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/mapeo-de-los-ganglios-linfaticos-mediante-un-tinte-fluorescente-en-el-cancer-de-colon 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/lymph-node-mapping-via-flourescent-dye-in-colon-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07621159/un-estudio-de-fase-ib-ii-de-hdm2017-en-combinacion-con-el-tratamiento-estandar-en-el-cancer-colorrectal-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621159/a-phase-ib-ii-study-of-hdm2017-in-combination-with-standard-of-care-in-advanced-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06167967/la-metilacion-del-adn-tumoral-circulante-como-guia-para-la-quimioterapia-adyuvante-postoperatoria-en-el-cancer-colorrectal-en-estadio-iii 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06167967/circulating-tumor-dna-methylation-guiding-postoperative-adjuvant-chemotherapy-in-stage-iii-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07623902/evaluacion-de-la-eficacia-de-gixam-para-predecir-la-presencia-de-neoplasia-colorrectal-avanzada-y-no-avanzada-en-una-poblacion-con-resultados-negativos-en-la-prueba-de-sangre-oculta-en-heces-fit 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07623902/evaluation-of-gixam-s-efficacy-predicting-the-presence-of-advanced-and-non-advanced-colorectal-neoplasia-in-a-fit-negative-population 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589440/estudio-de-fase-ii-de-sr-8541a-en-combinacion-con-botensilimab-y-balstilimab-en-sujetos-con-cancer-colorrectal-metastasico-resistente-al-tratamiento-y-con-estabilidad-de-microsatelites-mss-crc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589440/phase-2-study-of-sr-8541a-in-combination-with-botensilimab-and-balstilimab-in-subjects-with-refractory-metastatic-microsatellite-stable-colorectal-cancer-mss-crc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07321106/un-estudio-para-investigar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-actividad-antitumoral-de-cbi-1214-un-activador-de-celulas-t-en-participantes-con-cancer-colorrectal-avanzado-o 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07321106/a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-anti-tumor-activity-of-cbi-1214-t-cell-engager-in-participants-with-advanced-or-metastatic-mss-msi-l-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04564898/trifluridina-tipiracil-en-combinacion-con-capecitabina-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04564898/trifluridine-tipiracil-in-combination-with-capecitabine-and-bevacizumab-in-metastatic-colorectal-cancer-patients 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623174/un-estudio-de-fruquintinib-en-adultos-con-cancer-colorrectal-metastasico-en-polonia 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623174/a-study-of-fruquintinib-in-adults-with-metastatic-colorectal-cancer-in-poland 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06750094/un-estudio-de-amivantamab-y-folfiri-frente-a-cetuximab-bevacizumab-y-folfiri-en-participantes-con-cancer-colorrectal-kras-nras-y-braf-de-tipo-salvaje-que-previamente-han-recibido-quimioterapia 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06750094/a-study-of-amivantamab-and-folfiri-versus-cetuximab-bevacizumab-and-folfiri-in-participants-with-kras-nras-and-braf-wild-type-colorectal-cancer-who-have-previously-received-chemotherapy 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06547385/estudio-de-ono-4578-y-xelox-folfox-mas-bevacizumab-en-el-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06547385/study-of-ono-4578-and-xelox-folfox-plus-bevacizumab-in-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04034173/tratamiento-optimo-con-anti-egfr-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-ras-de-baja-frecuencia 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04034173/optimal-anti-egfr-treatment-of-mcrc-patients-with-low-frequency-ras-mutation 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595747/evaluacion-del-farmaco-antitumoral-rogaratinib-bay-1163877-para-el-tratamiento-del-sarcoma-avanzado-con-alteracion-en-el-receptor-del-factor-de-crecimiento-de-fibroblastos-fgfr-1-4-y-en-pacientes-con 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595747/testing-the-anti-cancer-drug-rogaratinib-bay-1163877-for-treatment-of-advanced-sarcoma-with-alteration-in-fibroblast-growth-factor-receptor-fgfr-1-4-and-in-patients-with-sdh-deficient 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06287723/estudio-frances-sobre-la-evaluacion-de-la-enfermedad-residual-minima-mediante-biopsias-liquidas-en-pacientes-con-cancer-colorrectal-y-metastasis-hepaticas-french-mrd-crlm 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06287723/french-assessment-of-mrd-by-liquid-biopsies-in-colorectal-with-liver-metastasis-patients-french-mrd-crlm 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06343116/nimotuzumab-en-combinacion-con-trifluridina-tipiracil-en-el-tratamiento-del-cancer-colorrectal-metastasico-refractario 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06343116/nimotuzumab-combined-with-trifluridine-tipiracil-in-the-treatment-of-refractory-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05704985/evaluacion-de-la-seguridad-y-los-biomarcadores-mediante-el-uso-de-dk210-egfr-en-tumores-localmente-avanzados-o-metastasicos-egfr 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05704985/evaluating-safety-and-biomarkers-using-dk210-egfr-for-locally-advanced-or-metastatic-egfr-tumors 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06646341/emvi-como-factor-determinante-de-la-metastasis-en-el-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06646341/emvi-as-a-determinant-of-metastasis-in-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980532/glumetinib-en-combinacion-con-fruquintinib-en-el-tratamiento-de-la-amplificacion-de-met-o-la-sobreexpresion-de-la-proteina-en-el-cancer-colorrectal-metastasico-irresecable-en-tercera-linea-de 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980532/glumetinib-combined-with-fruquintinib-in-the-treatment-of-met-amplification-or-protein-overexpression-in-third-line-unresectable-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07071844/between-bevacizumab-y-trifluridina-tipiracil-administrados-cada-dos-semanas-para-reducir-la-neutropenia-de-grado-3-4-en-pacientes-con-mcrc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07071844/between-biweekly-bevacizumab-trifluridine-tipiracil-to-reduce-grade-3-4-neutropenia-in-mcrc-patients 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04730544/dos-esquemas-de-tratamiento-combinados-con-nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-y-o-msi 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04730544/two-combination-treatment-regimens-of-nivolumab-and-ipilimumab-in-patients-with-dmmr-and-or-msi-mcrc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06665334/para-explorar-el-efecto-del-huaier-granule-en-la-tasa-de-conversion-a-negativo-despues-de-que-los-niveles-de-cea-vuelvan-a-aumentar-tras-la-cirugia-de-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06665334/to-explore-the-effect-of-huaier-granule-on-the-negative-conversion-rate-after-the-cea-level-increases-again-after-colorectal-cancer-surgery 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-en-combinacion-con-capeox-y-radioterapia-en-pacientes-con-cancer-colorrectal-metastasico-irresecable-de-tipo-mss 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-combined-with-capeox-and-radiotherapy-in-patients-with-unresectable-metastatic-mss-type-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04754672/entrenamiento-de-aptitud-aerobica-o-de-masa-muscular-para-mejorar-el-resultado-en-el-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04754672/aerobic-fitness-or-muscle-mass-training-to-improve-colorectal-cancer-outcome 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/un-estudio-exploratorio-de-biomarcadores-sobre-el-bloqueo-dual-de-pd1-pdl1-y-ctla4-y-la-terapia-antiangiogenica 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/a-biomarker-exploratory-study-of-dual-blockade-of-pd1-pdl1-and-ctla4-and-anti-angiogenic-therapy 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07649655/emb-01-en-combinacion-con-quimioterapia-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07649655/emb-01-in-combination-with-chemotherapy-for-unresectable-or-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04603287/un-estudio-de-si-b001-un-anticuerpo-bispecifico-anti-egfr-her3-en-tumores-epiteliales-localmente-avanzados-o-metastasicos 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04603287/a-study-of-si-b001-an-egfr-her3-bispecific-antibody-in-locally-advanced-or-metastatic-epithelial-tumors 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02484404/estudio-de-fase-i-ii-del-anticuerpo-anti-ligando-de-muerte-programada-1-durvalumab-medi4736-en-combinacion-con-olaparib-y-o-cediranib-para-tumores-solidos-avanzados-y-cancer-de-ovario-cancer-de-mama 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02484404/phase-i-ii-study-of-the-anti-programmed-death-ligand-1-durvalumab-antibody-medi4736-in-combination-with-olaparib-and-or-cediranib-for-advanced-solid-tumors-and-advanced-or-recurrent-ovarian-triple 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06867822/ensayo-clinico-de-proagio-en-cancer-colorrectal-avanzado-o-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06867822/trial-of-proagio-in-advanced-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07021950/ak112-mas-folfiri-frente-a-bevacizumab-mas-folfiri-como-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-mss-pmmr 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07021950/ak112-plus-folfiri-versus-bevacizumab-plus-folfiri-as-second-line-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06974110/estudio-de-moma-341-administrado-por-via-oral-en-participantes-con-tumores-solidos-avanzados-o-metastasicos 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974110/study-of-orally-administered-moma-341-in-participants-with-advanced-or-metastatic-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06841159/radioterapia-estereotactica-adaptativa-ultrafraccionada-y-personalizada-pulsar-combinada-con-terapia-anti-pd1-quimioterapia-y-terapia-dirigida-para-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06841159/personalized-ultrafractionated-stereotactic-adaptive-radiotherapy-pulsar-combined-with-anti-pd1-chemotherapy-and-target-therapy-for-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07271355/quimioterapia-intraabdominal-en-aerosol-a-presion-con-mitomicina-para-el-tratamiento-del-cancer-de-apendice-o-de-colon-recto-irresecable-con-metastasis-peritoneales-el-ensayo-impact 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07271355/pressurized-intraperitoneal-aerosolized-chemotherapy-with-mitomycin-for-the-treatment-of-unresectable-appendix-or-colorectal-cancer-with-peritoneal-metastases-the-impact-trial 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06018714/eficacia-del-fruquintinib-modificado-en-metastasis-hepaticas-del-cancer-colorrectal-un-estudio-de-fase-ii 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06018714/efficacy-of-modified-fruquintinib-in-colorectal-cancer-liver-metastases-a-phase-ii-study 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-en-combinacion-con-fruquintinib-y-radioterapia-estereotactica-ablativa-sbrt-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores-en-pacientes-con-crc-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-combined-with-fruquintinib-and-sbrt-as-athird-line-and-posterior-line-treatment-in-patients-with-mss-crc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05747716/terapia-de-radiacion-estereotactica-sbrt-combinada-con-fruquintinib-mas-un-anticuerpo-anti-pd-1-ctla-4-como-tratamiento-de-tercera-linea-en-pacientes-con-mcrc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05747716/sbrt-combined-with-fruquintinib-plus-pd-1-ctla-4-antibody-for-third-line-treatment-in-mcrc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07355764/ma-crc-ii-016-shr-1811 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06829355/estudio-de-inmunoterapia-con-timalfasina-y-regimen-triple-en-cancer-colorrectal-avanzado-mss-pmmr 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06829355/thymalfasin-immunotherapy-study-with-triple-regimen-in-advanced-mss-pmmr-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07261709/trifluridina-tipiracil-mas-fruquintinib-frente-a-trifluridina-tipiracil-mas-bevacizumab-en-cancer-colorrectal-metastasico-refractario-un-ensayo-aleatorizado-controlado-de-etiqueta-abierta-de-no 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07261709/trifluridine-tipiracil-plus-fruquintinib-vs-trifluridine-tipiracil-plus-bevacizumab-in-refractory-metastatic-colorectal-cancer-a-randomized-controlled-open-label-non-inferiority-trial 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07553572/aplicacion-digital-para-la-monitorizacion-remota-y-el-manejo-de-los-sintomas 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07553572/remote-monitoring-and-symptom-management-digital-application 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06134388/sulfasalazina-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06134388/sulfasalazine-in-patients-with-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980454/comparacion-de-la-farmacocinetica-en-la-fase-i-de-hlx05-frente-a-erbitux-r-en-hombres-chinos-sanos-seguridad-inmunogenicidad-y-farmacocinetica 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/phase-i-pk-comparison-of-hlx05-vs-erbitux-r-in-healthy-chinese-males-safety-immunogenicity-and-pharmacokinetics 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/inyeccion-intratumoral-de-ip-001-tras-ablacion-termica-en-pacientes-con-crc-nsclc-y-sts 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/intratumoral-injection-of-ip-001-following-thermal-ablation-in-patients-with-crc-nsclc-and-sts 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06497985/un-estudio-de-tucidinostat-en-combinacion-con-sintilimab-y-bevacizumab-en-pacientes-con-cancer-colorrectal-mss-pmmr 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06497985/a-study-of-tucidinostat-in-combination-with-sintilimab-and-bevacizumab-in-mss-pmmr-colorectal-cancer-patients 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05359393/una-terapia-combinada-que-incluye-inmunoterapia-anti-pd-1-en-cancer-de-recto-mss-con-metastasis-distal-resecable 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05359393/a-combination-therapy-including-anti-pd-1-immunotherapy-in-mss-rectal-cancer-with-resectable-distal-metastasis 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07044362/histotripsia-mas-quimioterapia-frente-a-quimioterapia-sola-en-metastasis-hepaticas-avanzadas-de-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044362/histotripsy-plus-chemotherapy-vs-chemotherapy-alone-for-advanced-colorectal-liver-metastasis 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07564908/correlacion-y-heterogeneidad-del-microambiente-inmunitario-y-los-patrones-de-crecimiento-histopatologicos-en-las-metastasis-hepaticas-del-cancer-colorrectal-que-pueden-ser-extirpadas-quirurgicamente 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07564908/correlation-and-heterogeneity-of-the-immune-microenvironment-and-histopathological-growth-patterns-in-resectable-colorectal-cancer-liver-metastases 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06192680/irinotecano-liposomal-y-capecitabina-mas-bevacizumab-como-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06192680/liposomal-irinotecan-and-capecitabine-plus-bevacizumab-as-second-line-therapy-in-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05556473/pet-ct-con-f-triptofano-en-canceres-humanos 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05556473/f-tryptophan-pet-ct-in-human-cancers 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05750953/intervencion-asistida-por-enfermeras-ehealth-hospital-2-home 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05750953/nurse-assisted-intervention-ehealth-hospital-2-home 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04304209/anticuerpo-anti-pd1-sintilimab-en-combinacion-con-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04304209/pd1-antibody-sintilimab-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06808685/estudio-nacional-multicentrico-en-el-mundo-real-para-evaluar-la-eficacia-y-la-seguridad-del-bevacizumab-biosimilar-elovie 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06808685/real-world-multicenter-national-study-to-evaluate-the-effectiveness-and-safety-of-biosimilar-bevacizumab-elovie 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04612309/estudio-retrospectivo-sobre-el-uso-de-inmunoterapia-en-pacientes-con-cancer-colorrectal-metastasico-msi-h 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04612309/retrospective-study-on-the-use-of-immunotherapy-in-patients-with-msi-h-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03485209/estudio-de-eficacia-y-seguridad-de-tisotumab-vedotina-en-pacientes-con-tumores-solidos 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03485209/efficacy-and-safety-study-of-tisotumab-vedotin-for-patients-with-solid-tumors 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05314400/gadoxetato-resonancia-magnetica-abreviada-en-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05314400/gadoxetate-abbreviated-mri-in-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT01792934/quimioterapia-y-reseccion-quirurgica-maxima-de-las-metastasis-de-cancer-colorrectal-multiorganico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT01792934/chemotherapy-and-maximal-tumor-debulking-of-multi-organ-colorectal-cancer-metastases 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07167446/potencial-neuroprotector-del-cannabidiol-cbd-en-la-prevencion-de-la-neuropatia-inducida-por-oxaliplatino-ox 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07167446/neuroprotective-potential-of-cannabidiol-cbd-in-preventing-oxaliplatin-ox-induced-neuropathy 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07570914/infusion-intraarterial-hepatica-de-irinotecan-liposomal-mas-oxaliplatino-y-capecitabina-como-terapia-adyuvante-para-metastasis-hepaticas-del-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07570914/hepatic-arterial-infusion-of-liposomal-irinotecan-plus-oxaliplatin-and-capecitabine-as-adjuvant-therapy-for-colorectal-cancer-liver-metastases 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05410977/recoleccion-de-muestras-de-sangre-y-heces-para-detectar-cancer-colorrectal-o-neoplasia-avanzada-en-pacientes-con-sindrome-de-lynch 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05410977/collecting-blood-and-stool-samples-to-detect-colorectal-cancer-or-advanced-neoplasia-in-lynch-syndrome-patients 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02754115/una-auditoria-de-la-cirugia-citorreductora-y-la-quimioterapia-intraperitoneal-hipertermica 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02754115/an-audit-of-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04547166/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-serplulimab-hlx10-en-combinacion-con-bevacizumab-hlx04-y-quimioterapia-xelox-en-pacientes-con-cancer-colorrectal-metastasico-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04547166/a-clinical-study-to-evaluate-efficacy-and-safety-of-serplulimab-hlx10-combined-with-bevacizumab-hlx04-and-chemotherapy-xelox-in-patients-with-metastatic-colorectal-cancer-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06057350/cirugia-frente-a-reseccion-endoscopica-para-el-cancer-de-colon-en-estadio-inicial-que-no-se-ha-eliminado-por-completo 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06057350/surgery-versus-endoscopic-resection-for-incompletely-removed-early-colon-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/una-base-de-datos-clinicobiologica-en-canceres-digestivos-metastasicos 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/a-clinicobiological-database-in-metastatic-digestive-cancers 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06220617/estudio-multi-omico-para-la-deteccion-temprana-del-cancer-colorrectal-moed-crc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06220617/multi-omics-study-for-early-detection-of-colorectal-cancer-moed-crc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06547203/cetuximab-irinotecan-y-toripalimab-en-un-estudio-de-cancer-colorrectal-derecho-ultra-seleccionado-con-mutaciones-ras-braf-de-tipo-salvaje 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06547203/cetuximab-irinotecan-toripalimab-in-ras-braf-wild-type-ultraselected-right-sided-colorectal-cancer-study 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05195710/radioembolizacion-preoperatoria-con-y-90-para-el-control-tumoral-y-la-hipertrofia-del-futuro-remanente-hepatico-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05195710/preoperative-y-90-radioembolization-for-tumor-control-and-future-liver-remnant-hypertrophy-in-patients-with-colorectal-liver-metastases 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07415031/un-estudio-de-tumores-solidos-para-el-tratamiento-a-largo-plazo-de-pacientes-con-cancer-que-participaron-en-estudios-con-adagrasib 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07415031/a-solid-tumor-study-for-long-term-treatment-of-cancer-patients-who-participated-in-adagrasib-studies 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02521844/un-estudio-para-evaluar-la-seguridad-y-la-tolerabilidad-de-etc-1922159-como-agente-unico-y-en-combinacion-con-pembrolizumab-en-tumores-solidos-avanzados 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02521844/a-study-to-evaluate-the-safety-and-tolerability-of-etc-1922159-as-a-single-agent-and-in-combination-with-pembrolizumab-in-advanced-solid-tumours 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06657222/primer-estudio-en-humanos-de-tub-030-en-pacientes-con-tumores-solidos-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06657222/first-in-human-study-of-tub-030-in-patients-with-advanced-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585035/estudio-para-evaluar-d-1553-en-sujetos-con-tumores-solidos 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585035/study-to-evaluate-d-1553-in-subjects-with-solid-tumors 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02906943/evaluacion-de-acidos-nucleicos-dirigida-a-tumores-en-toda-la-provincia-de-ontario 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02906943/ontario-wide-cancer-targeted-nucleic-acid-evaluation 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985109/kn-046-regorafenib-mas-otro-tratamiento-en-cancer-colorrectal-metastasico-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985109/kn-046-plus-regorafenib-in-mss-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824064/evaluacion-de-rbs2418-en-pacientes-con-cancer-colorrectal-avanzado-metastasico-y-en-progresion 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824064/evaluation-of-rbs2418-in-patients-with-advanced-metastatic-and-progressive-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06967155/un-estudio-de-irinotecan-con-dabrafenib-mas-trametinib-y-anti-egfr-en-la-segunda-linea-de-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06967155/a-study-of-irinotecan-with-dabrafenib-plus-trametinib-and-anti-egfr-in-the-second-line-of-therapy-in-people-with-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07653685/un-estudio-clinico-de-tqb2930-inyectable-y-quimioterapia-con-o-sin-bevacizumab-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07653685/a-clinical-study-of-tqb2930-injection-and-chemotherapy-with-or-without-bevacizumab-in-the-treatment-of-advanced-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959550/estudio-de-fase-ii-del-anticuerpo-biespecifico-anti-pd-1-vegf-ivonescimab-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959550/phase-ii-study-of-anti-pd-1-vegf-bispecific-antibody-ivonescimab-in-patients-with-previously-treated-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04579380/estudio-basket-con-tucatinib-y-trastuzumab-en-tumores-solidos-con-alteraciones-de-her2 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04579380/basket-study-of-tucatinib-and-trastuzumab-in-solid-tumors-with-her2-alterations 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07433283/nanoparticulas-de-carbono-cargadas-con-hierro-en-el-tratamiento-de-tumores-solidos-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433283/carbon-nanoparticle-loaded-iron-in-the-treatment-of-advanced-solid-tumor 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585750/evaluacion-de-pc14586-en-pacientes-con-tumores-solidos-avanzados-que-presentan-una-mutacion-y220c-en-el-gen-tp53-pynnacle 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585750/the-evaluation-of-pc14586-in-patients-with-advanced-solid-tumors-harboring-a-tp53-y220c-mutation-pynnacle 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06642844/quimioterapia-basada-en-bevacizumab-adaptada-a-la-farmacocinetica-del-bevacizumab-en-el-tratamiento-de-primera-linea 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06642844/bevacizumab-based-chemotherapy-adapted-to-bevacizumab-pharmacokinetics-in-1st-line-treatment 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-en-pacientes-con-carcinoma-colorrectal-metastasico-de-diagnostico-reciente 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-in-newly-diagnosed-metastatic-colorectal-carcinoma 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05572684/un-estudio-de-seguridad-tolerabilidad-y-eficacia-de-nc410-en-combinacion-con-pembrolizumab-en-participantes-con-tumores-solidos-avanzados-irresecables-o-metastasicos 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05572684/a-safety-tolerability-and-efficacy-study-of-nc410-plus-pembrolizumab-in-participants-with-advanced-unresectable-or-metastatic-solid-tumors 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07067385/vacuna-de-arnm-personalizada-contra-el-cancer-para-el-tratamiento-de-tumores-solidos-gastrointestinales 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07067385/personalized-mrna-cancer-vaccine-for-gastrointestinal-solid-tumor-treatment 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07253896/eficacia-y-seguridad-de-ak104-en-combinacion-con-quimioterapia-y-cetuximab-o-bevacizumab 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07253896/efficacy-and-safety-of-ak104-combined-with-chemotherapy-and-cetuximab-or-bevacizumab 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06885385/un-estudio-de-fase-ii-que-evalua-la-seguridad-y-la-eficacia-de-js207-con-o-sin-js015-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06885385/a-phase-2-study-evaluating-the-safety-and-efficacy-of-js207-with-or-without-js015-in-combination-with-chemotherapy-in-patients-with-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/inyeccion-intratumoral-it-de-vvdd-hil2-2-rg-1-para-tumores-metastasicos-gastrointestinales-y-peritoneales 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/intra-tumoral-it-injection-of-vvdd-hil2-2-rg-1-for-metastatic-gastrointestinal-and-peritoneal-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06946615/estudio-clinico-exploratorio-de-terapia-car-dc-y-car-t-dirigida-contra-claudin18-2-en-cancer-colorrectal-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06946615/exploratory-clinical-study-of-claudin18-2-targeted-car-dc-and-car-t-therapy-in-advanced-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07441369/abemaciclib-en-combinacion-con-los-regimenes-folfox-folfiri-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07441369/abemaciclib-combined-with-folfox-folfiri-regimen-in-patients-with-advanced-colorectal-liver-metastases-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03965234/perfusion-pulmonar-para-el-control-de-la-enfermedad-residual-minima-en-pacientes-con-sarcoma-o-metastasis-de-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03965234/pulmonary-suffusion-in-controlling-minimal-residual-disease-in-patients-with-sarcoma-or-colorectal-metastases 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04595266/quimioembolizacion-lifepearls-irinotecan-en-pacientes-con-cancer-colorrectal-y-enfermedad-metastasica 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595266/chemoembolization-lifepearls-irinotecan-in-patients-with-colorectal-cancer-and-metastatic-disease 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06253520/celulas-t-autologas-modificadas-geneticamente-para-expresar-receptores-reactivos-contra-las-mutaciones-de-kras-en-combinacion-con-una-vacuna-dirigida-contra-estos-antigenos-en-participantes-con 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06253520/autologous-t-cells-genetically-engineered-to-express-receptors-reactive-against-kras-mutations-in-conjunction-with-a-vaccine-directed-against-these-antigens-in-participants-with-metastatic-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06307548/cirugia-guiada-por-imagen-de-fluorescencia-seguida-de-terapia-fotodinamica-intraoperatoria-para-mejorar-el-control-tumoral-local-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-recurrente 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307548/fluorescence-image-guided-surgery-followed-by-intraoperative-photodynamic-therapy-for-improving-local-tumor-control-in-patients-with-locally-advanced-or-recurrent-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06760819/un-estudio-para-obtener-mas-informacion-sobre-la-eficacia-y-la-seguridad-del-tratamiento-con-tabletas-de-sevabertinib-bay-2927088-en-participantes-que-tienen-un-tumor-solido-con-mutaciones-del 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06760819/a-study-to-learn-more-about-how-well-treatment-with-sevabertinib-bay-2927088-tablets-works-and-how-safe-it-is-in-participants-who-have-a-solid-tumor-with-mutations-of-the-human-epidermal-growth 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-y-radioembolizacion-con-microsferas-de-166ho-en-el-cancer-colorrectal-metastasico-refractario 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-and-radioembolization-with-166ho-microspheres-in-refractory-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04687631/terapia-de-conversion-en-pacientes-con-cancer-colorrectal-ras-braf-tipo-salvaje-y-metastasis-hepaticas-inicialmente-irresecables 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04687631/conversion-therapy-of-ras-braf-wild-type-colorectal-cancer-patients-with-initially-unresectable-liver-metastases 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07462143/un-ensayo-clinico-de-fase-ii-iii-con-rc148-mas-quimioterapia-como-terapia-de-primera-linea-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07462143/a-phase-ii-iii-clinical-trial-of-rc148-plus-chemotherapy-as-1l-therapy-for-unresectable-or-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07692555/desarrollo-y-validacion-de-un-modelo-de-diagnostico-para-el-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07692555/development-and-validation-of-a-colorectal-cancer-diagnostic-model 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06896162/progreso-oncologia-de-precision-mediante-evaluaciones-genomicas-reflexivas-para-la-seleccion-de-estudios-y-la-supervivencia 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06896162/progress-precision-oncology-using-genomic-reflexive-evaluations-for-study-selection-and-survival 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07051785/fruquintinib-frente-a-bevacizumab-en-combinacion-con-irinotecan-liposomal-y-capecitabina-como-terapia-de-segunda-linea-para-el-cancer-colorrectal-metastasico-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07051785/fruquintinib-vs-bevacizumab-combined-with-irinotecan-liposome-and-capecitabine-as-second-line-therapy-for-advanced-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06243393/sacituzumab-govitecan-en-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06243393/sacituzumab-govitecan-in-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03164486/primer-estudio-en-humanos-mediante-tomografia-por-emision-de-positrones-que-utiliza-el-peptido-18f-v6 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03164486/first-in-human-positron-emission-tomography-study-using-the-18f-v6-binding-peptide 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06580574/inhibidores-de-los-puntos-de-control-inmunitario-para-la-preservacion-de-organos-en-canceres-gastricos-o-de-colon-no-metastasicos-con-dmmr-msi-h 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06580574/immune-checkpoint-inhibitors-for-organ-preservation-in-non-metastatic-dmmr-msi-h-gastric-or-colon-cancers 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05171660/combinacion-con-sintilimab-y-xelox-bevacizumab-como-terapia-de-primera-linea-en-el-cancer-colorrectal-metastasico-con-mutacion-en-los-genes-ras 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05171660/combination-with-sintilimab-and-xelox-bevacizumab-as-1st-line-therapy-in-ras-mutant-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07602504/base-de-datos-del-registro-clinico-chino-de-pacientes-con-cancer-de-higado-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07602504/china-metastatic-liver-cancer-clinical-registry-cohort-database 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07599501/suplementacion-nutricional-para-mejorar-la-cirugia-en-el-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07599501/nutritional-supplementation-to-improve-colorectal-cancer-surgery 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04245865/tocotrienol-y-bevacizumab-en-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04245865/tocotrienol-and-bevacizumab-in-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129774/quimiorradioterapia-seguida-de-cirugia-radical-en-pacientes-con-cancer-colorrectal-con-palnm 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129774/chemoradiotherapy-sequenced-radical-surgery-for-colorectal-cancer-with-palnm 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05832138/ensayo-onloop-evaluacion-de-un-nuevo-sistema-de-seguimiento-y-apoyo-para-los-supervivientes-de-cancer-infantil-en-ontario 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05832138/onloop-trial-evaluating-a-new-surveillance-and-support-system-for-survivors-of-childhood-cancer-in-ontario 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07587619/uso-intraoperatorio-de-la-imagen-de-saturacion-de-oxigeno-para-evaluar-la-perfusion-intestinal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07587619/intraoperative-use-of-oxygen-saturation-imaging-to-assess-intestinal-perfusion 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05815082/quimioterapia-adyuvante-guiada-por-ctdna-en-metastasis-hepaticas-del-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05815082/ctdna-guided-adjuvant-chemotherapy-in-liver-metastasis-of-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06685276/seguridad-y-eficacia-de-fruquintinib-mas-chidamide-y-sintilimab-en-el-tratamiento-de-tercera-linea-o-posterior-del-cancer-colorrectal-metastasico-mss-pmmr 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06685276/safety-and-efficacy-of-fruquintinib-plus-chidamide-and-sintilimab-in-the-third-and-later-line-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03828227/calidad-de-vida-en-pacientes-ancianos-con-cancer-colorrectal-metastasico-que-reciben-terapia-de-primera-linea-basada-en-parametros-geriatricos-simplificados 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03828227/qol-in-mcrc-elderly-patients-receiving-first-line-therapy-based-on-simplified-geriatric-parameters 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04329494/pipac-para-el-tratamiento-de-la-carcinomatosis-peritoneal-en-pacientes-con-cancer-de-ovario-utero-apendice-colon-o-estomago 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04329494/pipac-for-the-treatment-of-peritoneal-carcinomatosis-in-patients-with-ovarian-uterine-appendiceal-colorectal-or-gastric-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06435689/estudio-y-modulacion-de-las-respuestas-inmunitarias-en-los-canceres-colorrectales-primarios-y-metastasicos 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06435689/study-and-modulation-of-immune-responses-in-primary-and-metastatic-colon-cancers 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07050394/un-ensayo-de-expansion-de-dosis-de-hnf4-srrna-intravenoso-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07050394/a-dose-expansion-trial-of-intravenous-hnf4-srrna-for-unresectable-or-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03869892/estudio-de-fase-iii-sobre-el-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-que-no-son-candidatos-para-recibir-terapia-intensiva 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03869892/phase-iii-study-in-first-line-treatment-of-patients-with-metastatic-colorectal-cancer-who-are-not-candidate-for-intensive-therapy 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05705492/olanzapina-para-el-manejo-de-la-perdida-de-apetito-asociada-al-cancer-en-pacientes-con-cancer-avanzado-de-esofago-estomago-higado-pancreas-vias-biliares-colon-recto-o-pulmon 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05705492/olanzapine-for-the-management-of-cancer-associated-appetite-loss-in-patients-with-advanced-esophagogastric-hepatopancreaticobiliary-colorectal-or-lung-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07610707/ymn-a02-para-el-cancer-colorrectal-avanzado-con-pmmr-y-metastasis-hepaticas 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07610707/ymn-a02-for-advanced-pmmr-colorectal-cancer-with-liver-metastases 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07500298/estudio-de-fase-i-de-sar445877-en-combinacion-con-folfox6-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-estabilidad-de-microsatelites 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07500298/phase-1-study-of-sar445877-in-combination-with-folfox6-and-bevacizumab-as-first-line-treatment-for-microsatellite-stable-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992648/trifluridina-tipiracil-mas-regorafenib-frente-a-trifluridina-tipiracil-mas-bevacizumab-para-el-cancer-colorrectal-metastasico-refractario 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992648/trifluridine-tipiracil-plus-regorafenib-vs-trifluridine-tipiracil-plus-bevacizumab-for-refractory-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/un-estudio-de-ide034-en-participantes-adultos-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/a-study-of-ide034-in-adult-participants-with-locally-advanced-metastatic-solid-tumors-types 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06944548/evaluacion-del-efecto-de-la-actividad-fisica-adaptada-sobre-la-modificacion-del-metabolismo-lipidico-durante-la-quimioterapia-para-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06944548/evaluation-of-the-effect-of-adapted-physical-activity-on-the-modification-of-lipid-metabolism-during-chemotherapy-for-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07504523/terapia-celular-t-personalizada-ineo-vac-t01-en-cancer-colorrectal-avanzado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07504523/personalized-t-cell-therapy-ineo-vac-t01-in-advanced-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06111105/guia-mrd-01-crc-validacion-clinica-y-evaluacion-comparativa-de-los-mejores-diagnosticos-de-ctadn-en-el-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06111105/guide-mrd-01-crc-clinical-validation-and-benchmarking-of-top-performing-ctdna-diagnostics-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07622550/un-estudio-clinico-multicentrico-de-un-solo-brazo-que-evalua-la-combinacion-de-fruquintinib-con-serplulimab-y-quimioterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622550/a-single-arm-multicenter-clinical-study-of-fruquintinib-combined-with-serplulimab-and-chemotherapy-as-first-line-treatment-for-patients-with-ras-braf-mutated-advanced-colorectal-cance 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-mas-bevacizumab-y-quimioterapia-en-pacientes-con-cancer-colorrectal-mss-pmmr-sin-metastasis-hepaticas 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-plus-bevacizumab-and-chemotherapy-in-mss-pmmr-colorectal-with-no-liver-metastasis 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04188145/un-estudio-aleatorizado-de-fase-iii-que-compara-el-tratamiento-de-mantenimiento-con-fluoropirimidina-bevacizumab-frente-a-fluoropirimidina-despues-de-la-quimioterapia-de-induccion-en-pacientes-con 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04188145/a-randomized-phase-iii-study-comparing-maintenance-treatment-with-fluoropyrimidine-bevacizumab-versus-fluoropyrimidine-after-induction-chemotherapy-for-a-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/eficacia-y-seguridad-de-trifluridina-tipiracil-tas-102-en-combinacion-con-bevacizumab-y-putalimab-en-el-tratamiento-de-pacientes-con-cmmr-despues-de-una-cirugia-citoreductora-un-estudio-clinico-de-un 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/efficacy-and-safety-of-trifluridine-tipiracil-tas-102-combined-with-bevacizumab-and-serplulimab-in-patients-with-metastatic-colorectal-cancer-undergoing-cytoreductive-surgery-a-single-arm-single 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-una-vacuna-neoantigenica-personalizada-guiada-por-metodos-cuanticos-y-clasicos-para-el-cancer-colorrectal-en-estadio-iii-con-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-a-quantum-classical-guided-personalized-neoantigen-vaccine-for-mss-stage-iii-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303495/un-estudio-comparativo-de-folfiri-en-segunda-linea-bevacizumab-frente-a-irinotecan-bevacizumab-en-pacientes-con-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303495/a-study-of-2nd-line-folfiri-bevacizumab-vs-irinotecan-bevacizumab-in-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07334587/comparacion-de-la-eficacia-y-la-seguridad-entre-folfox-6-y-capox-en-el-carcinoma-colorrectal-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07334587/comparison-of-efficacy-and-safety-between-folfox-6-and-capox-in-metastatic-colorectal-carcinoma 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06663319/un-estudio-de-jnj-89402638-para-cancer-colorrectal-y-gastrico-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663319/a-study-of-jnj-89402638-for-metastatic-colorectal-and-gastric-cancers 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02012699/repositorio-integral-de-cancer-para-la-investigacion-oncologica 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02012699/integrated-cancer-repository-for-cancer-research 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-bey1107-en-combinacion-con-capecitabina-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/a-study-to-evaluate-safety-and-efficacy-of-bey1107-in-combination-with-capecitabine-in-patients-with-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06195111/un-estudio-en-el-mundo-real-de-un-regimen-que-contiene-trifluridina-tipiracil-para-el-tratamiento-de-pacientes-con-mcrc-estudio-reflect 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06195111/a-real-world-study-of-trifluridine-tipiracil-containing-regimen-for-the-treatment-of-patients-with-mcrc-reflect-study 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06665087/radioterapia-ultrafraccionada-guiada-por-cga-y-tratamiento-sistemico-de-primera-linea-en-pacientes-ancianos-o-fragiles-con-cmmr 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06665087/cga-guided-ultrafractionated-rt-and-first-line-systemic-treatment-in-elderly-or-frail-patients-with-mcrc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06543836/tratamiento-guiado-por-ctdna-con-tki-mas-inhibidor-de-pd-1-en-el-cancer-colorrectal-avanzado-pmmr-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06543836/ctdna-guided-treatment-of-tki-plus-pd-1-inhibitor-for-advanced-pmmr-mss-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06654037/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-abemaciclib-al-tratamiento-quimioterapeutico-habitual-5-fluorouracilo-para-el-cancer-colorrectal-metastasico-y-refractario 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06654037/testing-the-addition-of-an-anti-cancer-drug-abemaciclib-to-the-usual-chemotherapy-treatment-5-fluorouracil-for-metastatic-refractory-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05201352/evaluacion-de-la-eficacia-de-trifluridina-tipiracil-mas-un-anticuerpo-humano-verdadero-anti-il-1-frente-a-trifluridina-tipiracil-mas-placebo-en-pacientes-con-cancer-colorrectal-metastasico-despues 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201352/evaluation-of-efficacy-of-trifluridine-tipiracil-plus-an-anti-il-1-true-human-antibody-versus-trifluridine-tipiracil-plus-placebo-in-metastatic-colorectal-cancer-patients-after-failure-of-oxaliplatin 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02595931/m6620-e-hidrocloruro-de-irinotecan-en-el-tratamiento-de-pacientes-con-tumores-solidos-metastasicos-o-que-no-pueden-ser-extirpados-mediante-cirugia 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02595931/m6620-and-irinotecan-hydrochloride-in-treating-patients-with-solid-tumors-that-are-metastatic-or-cannot-be-removed-by-surgery 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05808790/metastasis-pulmonares-de-cancer-colorrectal-metastasis-pulmonar-versus-radioterapia-ablativa-estereotactica 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05808790/colorectal-pulmonary-metastases-pulmonary-metastasectomy-versus-stereotactic-ablative-radiotherapy 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07535632/radioterapia-estereotactica-ablativa-sbrt-seguida-de-un-inhibidor-de-pd-1-bevacizumab-y-tas-102-como-terapia-de-tercera-linea-para-el-cancer-colorrectal-recurrente-o-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07535632/sbrt-followed-by-pd-1-inhibitor-bevacizumab-and-tas-102-as-third-line-therapy-for-recurrent-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05609370/un-estudio-que-investiga-la-eficacia-y-la-seguridad-de-lbl-007-mas-tislelizumab-en-combinacion-con-bevacizumab-mas-fluoropirimidina-en-comparacion-con-bevacizumab-mas-fluoropirimidina-en 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05609370/a-study-investigating-the-efficacy-and-safety-of-alcestobart-lbl-007-plus-tislelizumab-in-combination-with-bevacizumab-plus-fluoropyrimidine-versus-bevacizumab-plus-fluoropyrimidine-in-participants 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614751/dat-2645-un-inhibidor-de-parg-como-monoterapia-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-que-presenten-alteraciones-de-perdida-de-funcion-en-brca1-2-y-o-otros-defectos-en-la-via-de 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614751/a-parg-inhibitor-dat-2645-monotherapy-in-patients-with-advanced-metastatic-solid-tumors-harboring-brca1-2-loss-of-function-alterations-and-or-other-defects-in-the-ddr-pathway 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07175636/ql1706-radioterapia-y-quimioterapia-a-corto-plazo-para-el-cancer-colorrectal-mss 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07175636/ql1706-with-short-course-radiotherapy-and-chemotherapy-for-mss-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03426904/quimioterapia-neoadyuvante-con-folfox-para-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03426904/neoadjuvant-folfox-chemotherapy-for-patients-with-locally-advanced-colon-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06820463/un-estudio-para-evaluar-los-eventos-adversos-y-la-eficacia-de-la-administracion-intravenosa-iv-de-telisotuzumab-adizutecan-en-combinacion-con-oxaliplatino-iv-fluorouracilo-acido-folinico-leucovorina 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/a-study-to-evaluate-the-adverse-events-and-efficacy-of-intravenous-iv-of-telisotuzumab-adizutecan-in-combination-with-iv-oxaliplatin-fluorouracil-folinic-acid-leucovorin-bevacizumab-panitumumab-in 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03526835/un-estudio-del-anticuerpo-bispecifico-mcla-158-en-pacientes-con-tumores-solidos-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03526835/a-study-of-bispecific-antibody-mcla-158-in-patients-with-advanced-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05629442/ctdna-y-preservacion-de-organos-respuesta-completa-patologica-en-el-cancer-de-recto 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05629442/ctdna-and-organ-preservation-pathologic-cr-in-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05787587/un-estudio-del-inhibidor-de-parg-ide161-en-participantes-con-tumores-solidos-avanzados 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05787587/a-study-of-parg-inhibitor-ide161-in-participants-with-advanced-solid-tumors 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05447611/papel-de-la-empatia-en-los-resultados-del-tratamiento-curativo-del-cancer-colorrectal-no-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05447611/role-of-empathy-in-curative-treatment-outcomes-of-non-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03449914/el-estudio-gold-g8-en-pacientes-de-edad-avanzada 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03449914/the-gold-study-g8-in-older-patients 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/terapia-anti-egfr-en-lineas-tempranas-para-facilitar-el-retratamiento-en-pacientes-seleccionados-con-mcrc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/early-line-anti-egfr-therapy-to-facilitate-retreatment-for-select-patients-with-mcrc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07025239/ql1706-en-inyeccion-combinado-con-bevacizumab-y-xelox-frente-a-placebo-combinado-con-bevacizumab-y-xelox-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-irresecable 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07025239/ql1706-injection-plus-bevacizumab-and-xelox-vs-placebo-plus-bevacizumab-and-xelox-as-first-line-treatment-of-unresectable-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07364656/analisis-de-la-presencia-y-los-efectos-sobre-la-funcion-cardiaca-de-los-autoanticuerpos-anti-nav1-5-en-pacientes-con-tumores-metastasicos 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07364656/analysis-of-the-presence-and-cardiac-functional-effects-of-anti-nav1-5-autoantibodies-in-patients-with-metastatic-tumors 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06403709/irinotecan-tas-102-mas-bevacizumab-como-terapia-de-tercera-linea-o-posterior-en-pacientes-con-mcrc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06403709/irinotecan-tas-102-plus-bevacizumab-as-a-third-line-or-beyond-therapy-in-mcrc-patients 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05985954/estudio-de-fase-1b-abierto-con-ulixertinib-y-cetuximab-o-ulixertinib-en-combinacion-con-cetuximab-y-encorafenib-en-pacientes-con-cancer-colorrectal-irresecable-o-metastasico-que-previamente-han 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985954/open-label-phase-1b-study-of-ulixertinib-and-cetuximab-or-ulixertinib-in-combination-with-cetuximab-and-encorafenib-in-patients-with-unresectable-or-metastatic-colorectal-cancer-who-have-previously 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07559760/nueva-terapia-combinada-de-segunda-linea-para-el-cancer-colorrectal-metastasico-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07559760/new-second-line-combo-therapy-for-mss-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645236/dhf-20-1839-2-protocolo-del-estudio-clinico-de-rendimiento-para-el-kit-therascreen-r-kras-rgq-pcr 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645236/dhf-20-1839-2-clinical-performance-study-protocol-for-therascreen-r-kras-rgq-pcr-kit 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06268015/optimizacion-de-botensilimab-y-balstilimab-en-el-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06268015/botensilimab-and-balstilimab-optimization-in-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07262619/eik1005-002-un-estudio-de-investigacion-clinica-que-evalua-eik1005-un-inhibidor-de-la-helicasa-de-werner-como-monoterapia-y-en-combinacion-con-pembrolizumab-en-participantes-con-tumores-solidos 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07262619/eik1005-002-a-clinical-research-study-evaluating-eik1005-a-werner-helicase-inhibitor-as-monotherapy-and-in-combination-with-pembrolizumab-in-participants-with-advanced-solid-tumors-including 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05217446/un-estudio-de-encorafenib-mas-cetuximab-administrados-en-combinacion-con-pembrolizumab-en-comparacion-con-pembrolizumab-solo-en-pacientes-con-cancer-colorrectal-metastasico-no-tratado-previamente 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05217446/a-study-of-encorafenib-plus-cetuximab-taken-together-with-pembrolizumab-compared-to-pembrolizumab-alone-in-people-with-previously-untreated-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07385521/el-uso-de-la-inteligencia-artificial-para-la-prediccion-de-la-recurrencia-tras-la-reseccion-de-metastasis-hepaticas-de-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07385521/the-use-of-artificial-intelligence-for-the-prediction-of-recurrence-after-resection-of-colorectal-liver-metastases 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05513716/caracterizacion-molecular-de-las-metastasis-peritoneales-del-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05513716/molecular-characterisation-of-colorectal-cancer-peritoneal-metastases 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03428477/epa-para-el-ensayo-clinico-sobre-metastasis-2 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03428477/epa-for-metastasis-trial-2 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07389265/continuacion-del-tratamiento-con-cetuximab-tras-la-progresion-en-primera-linea-en-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07389265/continuation-of-cetuximab-beyond-first-line-progression-in-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07392567/validacion-prospectiva-de-un-modelo-de-inteligencia-artificial-para-predecir-la-metastasis-hepatica-en-el-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07392567/prospective-validation-of-an-ai-model-for-predicting-liver-metastasis-in-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07391566/lpm6690176-en-combinacion-con-quimioterapia-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-ras 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07391566/lpm6690176-in-combination-with-chemotherapy-and-bevacizumab-in-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05720559/estrategia-de-bloqueo-temprano-para-la-metastasis-hepatica-sincronica-del-cancer-colorrectal-basada-en-la-deteccion-prehepatica-de-ctc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05720559/early-blocking-strategy-for-metachronous-liver-metastasis-of-colorectal-cancer-based-on-pre-hepatic-ctc-detection 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07399236/prediccion-basada-en-inteligencia-artificial-de-la-metastasis-hepatica-en-el-cancer-colorrectal-un-estudio-retrospectivo 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07399236/ai-based-prediction-of-liver-metastasis-in-colorectal-cancer-a-retrospective-study 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07410676/ebnk-001-celulas-nk-alogenicas-con-dosis-bajas-de-il-15-pembrolizumab-en-tumores-solidos-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07410676/ebnk-001-allogeneic-nk-cells-with-low-dose-il-15-pembrolizumab-in-advanced-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277322/dupilumab-y-toripalimab-como-tratamiento-neoadyuvante-en-sujetos-con-crc-mss-y-metastasis-hepaticas-resecables 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277322/neoadjuvant-dupilumab-and-toripalimab-in-mss-crc-subjects-with-resectable-liver-metastases 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04743102/biopsia-multipunto-y-de-espesor-total-en-el-diagnostico-de-respuesta-clinica-completa-ccr-tras-la-terapia-neoadyuvante-para-el-cancer-de-recto 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04743102/multi-points-and-full-thickness-biopsy-in-the-diagnosis-of-ccr-after-neoadjuvant-therapy-for-rectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06191120/imagenes-moleculares-con-fapi-para-el-diagnostico-del-subtipo-desfavorable-cms4-de-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06191120/fapi-molecular-imaging-for-diagnosis-of-the-cms4-unfavorable-colorectal-cancer-subtype 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT01174121/inmunoterapia-con-linfocitos-infiltrantes-tumorales-para-pacientes-con-cancer-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT01174121/immunotherapy-using-tumor-infiltrating-lymphocytes-for-patients-with-metastatic-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-en-monoterapia-y-en-combinacion-con-pembrolizumab-en-pacientes-con-cancer-colorrectal-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-alone-and-in-combination-with-pembrolizumab-in-patients-with-colorectal-cancer-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02980510/comparacion-de-folfirinox-con-panitumumab-frente-a-mfolfox6-con-panitumumab-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-b-raf-de-tipo-salvaje 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02980510/comparison-folfirinox-panitumumab-vs-mfolfox6-panitumumab-in-ras-b-raf-wild-type-metastatic-colorectal-cancer-patients 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06226857/otras-mutaciones-en-oncogenes-que-podrian-influir-en-la-eficacia-de-los-tratamientos-anti-egfr-en-pacientes-con-cancer-colorrectal-metastasico-de-lado-izquierdo-y-con-ras-de-tipo-salvaje 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06226857/other-oncogene-mutations-for-anti-egfr-efficacy-in-patients-with-left-sided-ras-wild-type-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06746545/un-estudio-clinico-prospectivo-de-etiqueta-abierta-de-un-solo-brazo-de-fase-ii-para-evaluar-la-combinacion-de-fruquintinib-con-s-1-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06746545/a-prospective-open-label-single-arm-phase-ii-clinical-study-of-fruquintinib-combined-with-s-1-for-the-treatment-of-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04714957/pitcher-heterogeneidad-de-la-carcinomatosis-peritoneal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04714957/pitcher-peritoneal-carcinomatosis-heterogeneity 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT00569127/octreotido-acetato-e-interferon-alfa-2b-recombinante-o-bevacizumab-en-el-tratamiento-de-pacientes-con-tumor-neuroendocrino-metastasico-o-localmente-avanzado-de-alto-riesgo 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT00569127/octreotide-acetate-and-recombinant-interferon-alfa-2b-or-bevacizumab-in-treating-patients-with-metastatic-or-locally-advanced-high-risk-neuroendocrine-tumor 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05379595/un-estudio-de-amivantamab-en-monoterapia-y-en-combinacion-con-la-quimioterapia-estandar-en-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05379595/a-study-of-amivantamab-monotherapy-and-in-addition-to-standard-of-care-chemotherapy-in-participants-with-advanced-or-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06374173/un-estudio-de-fase-i-para-evaluar-tgi-6-en-sujetos-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06374173/a-phase-1-study-to-evaluate-tgi-6-in-subjects-with-locally-advanced-metastatic-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-solo-o-en-combinacion-con-radioterapia-hipofraccionada-de-baja-dosis-mas-toripalimab-para-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-alone-or-in-combination-with-hypofractionated-low-dose-radiotherapy-plus-toripalimab-for-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/un-estudio-de-mrg007-arr-217-en-pacientes-con-tumores-solidos-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/a-study-of-mrg007-arr-217-in-patients-with-advanced-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04929223/un-estudio-que-evalua-la-seguridad-y-la-eficacia-de-las-terapias-dirigidas-en-subpoblaciones-de-pacientes-con-cancer-colorrectal-metastasico-intrinsic 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04929223/a-study-evaluating-the-safety-and-efficacy-of-targeted-therapies-in-subpopulations-of-patients-with-metastatic-colorectal-cancer-intrinsic 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/eficacia-y-seguridad-de-tunlametinib-mas-vemurafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/efficacy-and-safety-of-tunlametinib-plus-vemurafenib-in-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06275958/estudio-de-dosis-quimioterapia-con-dosis-reducidas-en-primera-linea-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06275958/dosage-study-upfront-dose-reduced-chemotherapy-in-older-patients-with-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854668/un-estudio-de-la-combinacion-de-anlotinib-clorhidrato-en-capsulas-con-quimioterapia-como-tratamiento-de-primera-linea-en-sujetos-con-cancer-colorrectal-metastasico-ras-braf-tipo-salvaje 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04854668/a-study-of-anlotinib-hydrochloride-capsule-combined-with-chemotherapy-as-first-line-treatment-in-subjects-with-ras-braf-wild-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008030/un-estudio-de-nivolumab-nivolumab-mas-ipilimumab-o-quimioterapia-a-eleccion-del-investigador-para-el-tratamiento-de-participantes-con-cancer-colorrectal-metastasico-mcrc-con-deficiencia-en-la 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008030/a-study-of-nivolumab-nivolumab-plus-ipilimumab-or-investigator-s-choice-chemotherapy-for-the-treatment-of-participants-with-deficient-mismatch-repair-dmmr-microsatellite-instability-high-msi-h 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05250648/ensayo-clinico-sobre-la-administracion-de-hipec-con-mitomicina-c-en-metastasis-peritoneales-del-cancer-de-colon-gecop-mmc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05250648/clinical-trial-on-hipec-with-mitomycin-c-in-colon-cancer-peritoneal-metastases-gecop-mmc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04430725/ablacion-por-microondas-o-reseccion-en-cuna-para-el-tratamiento-de-lesiones-pulmonares-de-sarcoma-y-colorrectales-estudio-allume 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430725/microwave-ablation-or-wedge-resection-for-the-treatment-of-lung-sarcoma-and-colorectal-lesions-allume-study 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05008809/quimioterapia-post-reseccion-ablacion-en-pacientes-con-cancer-colorrectal-metastasico-fire-9-port-aio-krk-0418 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05008809/post-resection-ablation-chemotherapy-in-patients-with-metastatic-colorectal-cancer-fire-9-port-aio-krk-0418 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07693751/un-estudio-que-evalua-el-farmaco-sot109-por-primera-vez-en-pacientes-con-el-objetivo-de-determinar-su-seguridad-eficacia-y-como-el-organismo-lo-metaboliza-en-pacientes-con-cancer-colorrectal-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07693751/a-study-testing-sot109-for-the-first-time-in-patients-to-assess-how-safe-sot109-is-how-well-it-works-and-how-the-body-handles-it-in-patients-with-advanced-colorectal-cancer-that-can-not-be-removed-by 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06252649/estudio-de-sotorasib-panitumumab-y-folfiri-frente-a-folfiri-con-o-sin-bevacizumab-en-participantes-con-cancer-colorrectal-metastasico-con-mutacion-kras-p-g12c-que-no-han-recibido-tratamiento-previo 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252649/study-of-sotorasib-panitumumab-and-folfiri-versus-folfiri-with-or-without-bevacizumab-awwb-in-treatment-naive-participants-with-metastatic-colorectal-cancer-with-kras-p-g12c-mutation 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03740503/investigacion-genomica-de-pacientes-con-respuestas-inusuales 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03740503/genomic-investigation-of-unusual-responders 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213570/stream-2-tratamiento-de-segunda-linea-con-regorafenib-en-cancer-colorrectal-avanzado-con-mutacion-en-ras 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213570/stream-2-second-line-treatment-with-regorafenib-in-advanced-ras-mutant-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07263178/un-estudio-sobre-la-quimioterapia-paliativa-en-segunda-linea-y-posteriores-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07263178/a-study-of-second-and-later-line-palliative-chemotherapy-in-patients-with-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/deteccion-temprana-del-fracaso-del-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/early-detection-of-treatment-failure-in-metastatic-colorectal-cancer-patients 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085091/un-estudio-de-fase-i-en-humanos-con-alx2004-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-seleccionados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085091/a-first-in-human-study-of-alx2004-with-advanced-or-metastatic-selected-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283575/uso-de-la-metilacion-del-ctdna-para-monitorizar-el-tratamiento-del-cancer-colorrectal-metastasico-promet 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283575/using-ctdna-methylation-to-monitor-metastatic-colorectal-cancer-treatment-promet 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05283330/seguridad-y-tolerabilidad-de-212pb-dotam-grpr1-en-sujetos-adultos-con-tumores-recurrentes-o-metastasicos-que-expresan-grpr 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05283330/safety-and-tolerability-of-212pb-dotam-grpr1-in-adult-subjects-with-recurrent-or-metastatic-grpr-expressing-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07286695/fruquintinib-en-combinacion-con-trifluridina-tipiracil-frente-a-bevacizumab-en-combinacion-con-trifluridina-tipiracil-para-el-cancer-colorrectal-metastasico-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07286695/fruquintinib-combined-with-trifluridine-tipiracil-versus-bevacizumab-combined-with-trifluridine-tipiracil-for-advanced-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07705334/un-estudio-de-shy-onc6-un-nuevo-inhibidor-del-proteasoma-en-adultos-con-tumores-solidos-avanzados-o-metastasicos 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07705334/a-study-of-shy-onc6-a-novel-proteasome-inhibitor-in-adults-with-advanced-or-metastatic-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663839/un-estudio-de-nilk-2301-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-metastasico-con-bajo-volumen-tumoral-ltv 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663839/a-study-of-nilk-2301-in-patients-with-locally-advanced-or-metastatic-low-tumor-volume-ltv-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05727163/folfox-administrado-por-via-hai-mas-irinotecan-intravenoso-con-o-sin-bevacizumab-frente-a-folfoxiri-sistemico-con-o-sin-bevacizumab-en-pacientes-con-metastasis-hepaticas-colorrectales-crlm 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05727163/folfox-via-hai-plus-intravenous-irinotecan-with-or-without-bevacizumab-versus-systemic-folfoxiri-with-or-without-bevacizumab-in-initially-unresectable-ras-mutated-crlm-patients 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05262491/un-estudio-de-bl-b01d1-en-pacientes-con-tumor-gastrointestinal-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05262491/a-study-of-bl-b01d1-in-patients-with-locally-advanced-or-metastatic-gastrointestinal-tumor-and-other-solid-tumor 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03326791/aspirina-en-metastasis-hepaticas-del-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03326791/aspirin-in-colorectal-cancer-liver-metastases 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07474025/integracion-de-los-patrones-de-crecimiento-histologico-peritoneal-en-la-toma-de-decisiones-preoperatorias-para-las-metastasis-peritoneales-del-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07474025/integrating-peritoneal-histological-growth-patterns-into-preoperative-decision-making-for-colorectal-peritoneal-metastses 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07714447/eficacia-y-seguridad-de-la-terapia-combinada-con-tunlametinib-en-el-tratamiento-del-cancer-colorrectal-metastasico-en-segunda-linea-o-posterior 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07714447/efficacy-and-safety-of-tunlametinib-combination-therapy-in-the-treatment-of-second-line-and-above-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07244705/un-estudio-de-abt-301-mas-tislelizumab-con-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-metastasico-pmmr-no-msi-h 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07244705/a-study-of-abt-301-plus-tislelizumab-with-bevacizumab-in-pmmr-non-msi-h-locally-advanced-or-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-y-uso-de-g-csf-mantener-la-dosis-e-intensidad-adecuadas-para-optimizar-la-eficacia-del-tratamiento 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-and-g-csf-use-being-on-a-right-dose-intensity-to-optimize-treatment-efficacy 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07486492/utilizando-bacterias-beneficiosas-del-intestino-para-potenciar-el-tratamiento-inmunologico-del-cancer-colorrectal-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07486492/using-healthy-gut-bacteria-to-boost-immune-treatment-for-advanced-bowel-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224841/desarrollo-de-un-panel-de-biomarcadores-basado-en-la-metilacion-de-la-cfdna-5mc-5hmc-para-predecir-la-eficacia-de-las-terapias-dirigidas-en-el-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224841/development-of-a-cfdna-5mc-5hmc-based-biomarker-panel-to-predict-targeted-therapy-efficacy-in-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/ensayo-collision-relapse 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/collision-relapse-trial 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02246634/deteccion-de-metastasis-sincronicas-en-el-cancer-colorrectal-mediante-resonancia-magnetica-con-difusion-serenade 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02246634/screening-for-synchronous-metastases-in-colorectal-cancer-with-dw-mri-serenade 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05608044/un-estudio-de-botensilimab-y-balstilimab-para-el-tratamiento-del-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05608044/a-study-of-botensilimab-and-balstilimab-for-the-treatment-of-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05691491/evaluacion-de-la-combinacion-de-los-farmacos-antineoplasicos-temozolomida-y-m1774-para-determinar-su-seguridad-y-eficacia 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05691491/testing-the-combination-of-the-anti-cancer-drugs-temozolomide-and-m1774-to-evaluate-their-safety-and-effectiveness 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05719558/un-estudio-de-asp1002-en-adultos-para-el-tratamiento-de-tumores-solidos 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05719558/a-study-of-asp1002-in-adults-for-treatment-of-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05425940/estudio-de-xl092-atezolizumab-frente-a-regorafenib-en-participantes-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05425940/study-of-xl092-atezolizumab-vs-regorafenib-in-participants-with-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-y-envafolimab-mas-mfolfoxiri-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-irresecable-del-lado-izquierdo-con-ras-braf-de-tipo-salvaje-y-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-and-envafolimab-plus-mfolfoxiri-as-first-line-treatment-for-ras-braf-wild-type-mss-unresectable-left-side-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06445062/estudio-de-inhibidores-de-ras-on-en-pacientes-con-tumores-solidos-gastrointestinales 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06445062/study-of-ras-on-inhibitors-in-patients-with-gastrointestinal-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06826092/metformina-para-el-tratamiento-de-pacientes-con-mcrc-que-reciben-folfiri-mas-terapia-dirigida 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06826092/metformin-for-the-treatment-of-mcrc-patients-undergoing-folfiri-plus-target-therapy 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07007689/un-estudio-multi-omico-del-cancer-colorrectal-con-mutacion-braf-v600e 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007689/a-multi-omics-study-of-braf-v600e-mutant-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04771520/avapritinib-para-el-tratamiento-de-tumores-solidos-malignos-localmente-avanzados-o-metastasicos-con-mutacion-en-ckit-o-pdgfra 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04771520/avapritinib-for-the-treatment-of-ckit-or-pdgfra-mutation-positive-locally-advanced-or-metastatic-malignant-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07007728/iparolimab-tuvonralimab-en-combinacion-con-bevacizumab-y-capeox-como-terapia-de-conversion-para-metastasis-hepaticas-del-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007728/iparomlimab-tuvonralimab-combined-with-bevacizumab-and-capeox-as-conversion-therapy-for-colorectal-cancer-liver-metastasis 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06283134/un-estudio-clinico-de-biottt001-en-combinacion-con-toripalimab-y-regorafenib-en-pacientes-con-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06283134/a-clinical-study-of-biottt001-in-combination-with-toripalimab-and-regorafenib-in-patients-with-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03947385/estudio-de-ide196-en-pacientes-con-tumores-solidos-que-presentan-mutaciones-en-gnaq-11-o-fusiones-en-prkc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03947385/study-of-ide196-in-patients-with-solid-tumors-harboring-gnaq-11-mutations-or-prkc-fusions 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221357/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-pumitamig-en-combinacion-con-quimioterapia-frente-a-bevacizumab-en-combinacion-con-quimioterapia-en-participantes-con-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221357/a-study-to-evaluate-the-safety-and-efficacy-of-pumitamig-in-combination-with-chemotherapy-versus-bevacizumab-in-combination-with-chemotherapy-in-participants-with-previously-untreated-unresectable-or 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06776757/sintilimab-en-combinacion-con-cetuximab-y-quimioterapia-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-avanzado-con-ras-braf-de-tipo-salvaje 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06776757/sintilimab-in-combination-with-cetuximab-and-chemotherapy-as-first-line-treatment-for-ras-braf-wild-type-advanced-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03983993/niraparib-y-panitumumab-en-pacientes-con-cancer-colorrectal-avanzado-o-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03983993/niraparib-and-panitumumab-in-patients-with-advanced-or-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06202183/ejercicio-fisico-y-microbiota-intestinal-en-pacientes-con-cancer-colorrectal-de-inicio-temprano-que-reciben-quimioterapia-el-ensayo-courage 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202183/exercise-for-gut-microbiome-in-patients-with-young-onset-colorectal-cancer-undergoing-chemotherapy-the-courage-trial 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440005/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-y-la-actividad-preliminar-de-agx101-en-participantes-con-tumores-solidos-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440005/a-study-to-evaluate-safety-tolerability-and-preliminary-activity-of-agx101-in-participants-with-advanced-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04798898/mejora-de-la-supervivencia-en-metastasis-hepaticas-de-cancer-colorrectal-mediante-la-inmunostimulacion-inducida-por-ablacion-por-radiofrecuencia 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04798898/improving-survival-of-colorectal-liver-metastases-by-rfa-mediated-immunostimulation 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07623369/un-estudio-de-fase-i-en-humanos-con-hh160-en-pacientes-con-tumores-solidos-avanzados 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623369/a-first-in-human-study-of-hh160-in-patients-with-advanced-solid-tumors 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06077591/validacion-clinica-prospectiva-de-la-secuenciacion-de-nueva-generacion-ngs-y-la-terapia-guiada-mediante-organoides-tumorales-derivados-del-paciente-pdo-en-pacientes-con-tumores-solidos-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06077591/prospective-clinical-validation-of-next-generation-sequencing-ngs-and-patient-derived-tumor-organoids-pdo-guided-therapy-in-patients-with-advanced-inoperable-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07031570/eficacia-y-seguridad-de-la-combinacion-de-deb-tace-con-haic-frente-a-haic-sola-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal-crlm 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07031570/efficacy-and-safety-of-deb-tace-combined-with-haic-versus-haic-alone-in-patients-with-unresectable-crlm 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623642/un-estudio-de-fase-ii-de-gv20-0251-en-combinacion-con-anticuerpos-monoclonales-anti-pd-1-en-pacientes-con-tumores-solidos-irresecables-localmente-avanzados-o-metastasicos 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623642/a-phase-ii-study-of-gv20-0251-in-combination-with-anti-pd-1-monoclonal-antibodies-in-patients-with-unresectable-locally-advanced-or-metastatic-solid-tumors 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04046445/estudio-de-fase-1b-para-evaluar-atp128-vsv-gp128-y-bi-754091-en-pacientes-con-cancer-colorrectal-en-estadio-iv 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04046445/phase-1b-study-to-evaluate-atp128-vsv-gp128-and-bi-754091-in-patients-with-stage-iv-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321847/inyeccion-de-ip-001-en-tumores-hepaticos-sometidos-a-ablacion-termica-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321847/injection-of-ip-001-into-thermally-ablated-hepatic-tumors-in-patients-with-colorectal-liver-metastases 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07515963/fuliri-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-la-terapia-de-conversion-de-metastasis-hepaticas-del-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07515963/fuliri-plus-targeted-therapy-for-first-line-conversion-therapy-of-colorectal-cancer-liver-metastases 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06699836/ensayo-de-fase-ii-clover-que-evalua-el-uso-de-leronlimab-un-farmaco-dirigido-al-ccr5-en-combinacion-con-quimioterapia-oral-y-un-regimen-enriquecido-con-un-inhibidor-del-vegf 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06699836/the-phase-2-ccr5-targeting-leronlimab-with-oral-chemotherapy-and-vegf-inhibitor-enriched-regimen-trial-clover 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06992258/un-ensayo-aleatorizado-de-fase-ii-que-compara-fruquintinib-y-tas-102-con-fruquintinib-en-pacientes-con-cancer-colorrectal-avanzado-metastasico-refractario 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992258/a-randomized-phase-2-trial-of-fruquintinib-and-tas-102-as-compared-to-fruquintinib-in-patients-with-refractory-advanced-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04014530/pembrolizumab-en-combinacion-con-ataluren-en-pacientes-con-carcinoma-colorrectal-metastasico-pmmr-y-dmmr-o-carcinoma-endometrial-metastasico-dmmr-el-estudio-atapembro 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04014530/pembrolizumab-with-ataluren-in-patients-with-metastatic-pmmr-and-dmmr-colorectal-carcinoma-or-metastatic-dmmr-endometrial-carcinoma-the-atapembro-study 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04584008/evaluacion-de-agentes-dirigidos-en-canceres-digestivos-en-china-basada-en-las-caracteristicas-moleculares 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04584008/targeted-agent-evaluation-in-digestive-cancers-in-china-based-on-molecular-characteristics 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-in-patients-with-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07094204/un-estudio-para-determinar-una-dosis-adecuada-de-asp5834-en-adultos-con-tumores-solidos 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07094204/a-study-to-find-a-suitable-dose-of-asp5834-in-adults-with-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06184698/irinotecan-liposomal-y-leucovorina-5-fluorouracilo-mas-bevacizumab-en-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06184698/liposomal-irinotecan-and-leucovorin-5-fluorouracil-plus-bevacizumab-in-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07525206/un-estudio-para-evaluar-el-uso-de-telisotuzumab-adizutecan-intravenoso-iv-en-combinacion-con-bevacizumab-iv-en-comparacion-con-el-tratamiento-estandar-con-bevacizumab-iv-en-combinacion-con 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07525206/a-study-to-access-intravenous-iv-telisotuzumab-adizutecan-in-combination-with-iv-bevacizumab-compared-to-standard-of-care-iv-bevacizumabin-combination-with-oral-trifluridine-and-tipiracil-in-adult 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05746897/un-estudio-de-fase-i-abierto-multicentrico-y-de-primera-administracion-en-humanos-de-nm1f-anti-pvrig-en-pacientes-con-tumores-solidos-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05746897/a-first-in-human-phase-i-open-label-multicenter-study-of-nm1f-anti-pvrig-in-patients-with-advanced-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04689347/5fu-lv-irinotecan-temozolomida-y-bevacizumab-para-el-cancer-colorrectal-metastasico-con-metilacion-del-gen-mgmt-y-estabilidad-de-microsatelites 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04689347/5fu-lv-irinotecan-temozolomide-and-bevacizumab-for-mgmt-silenced-microsatellite-stable-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06107413/estudio-para-evaluar-los-eventos-adversos-y-los-cambios-en-la-actividad-de-la-enfermedad-en-participantes-adultos-previamente-tratados-que-reciben-abbv-400-por-via-intravenosa-iv-en-combinacion-con 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06107413/study-to-assess-adverse-events-and-change-in-disease-activity-in-previously-treated-adult-participants-receiving-intravenous-iv-abbv-400-with-unresectable-metastatic-colorectal-cancer-in-combination 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07631884/estudio-exploratorio-sobre-la-eficacia-y-la-seguridad-del-trastuzumab-rezetecan-en-el-tratamiento-de-tumores-solidos-avanzados-con-expresion-de-her2 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07631884/exploratory-study-on-the-efficacy-and-safety-of-trastuzumab-rezetecan-in-the-treatment-of-her2-expressiong-advanced-solid-tumor 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05131919/pembrolizumab-para-el-tratamiento-de-cancer-colorrectal-localmente-avanzado-irresecable-y-no-metastasico-con-dmmr 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05131919/pembrolizumab-for-locally-advanced-irresectable-non-metastatic-dmmr-colorectal-cancers 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06050447/factores-que-afectan-los-resultados-del-tratamiento-en-pacientes-con-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06050447/factors-affecting-the-results-of-treatment-of-patients-with-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06395519/un-estudio-del-inhibidor-de-parg-etx-19477-en-pacientes-con-tumores-solidos-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06395519/a-study-of-parg-inhibitor-etx-19477-in-patients-with-advanced-solid-malignancies 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07042685/ensayo-clinico-de-una-terapia-basada-en-5-fluorouracilo-5-fu-en-combinacion-con-fruquintinib-en-pacientes-con-cancer-colorrectal-localmente-avanzado-irresecable-o-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07042685/trial-of-5-fluorouracil-5fu-based-therapy-in-combination-with-fruquintinib-in-patients-with-locally-advanced-unresectable-or-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07333651/implante-de-semillas-de-125i-mas-terapia-sistemica-para-el-cancer-de-pulmon-de-celulas-no-pequenas-cpcnp-u-el-cancer-colorrectal-oligoprogresivo 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/125i-seed-implantation-plus-systemic-therapy-for-oligoprogressive-nsclc-or-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07035886/un-estudio-para-monitorizar-el-tratamiento-con-fruzaqla-en-adultos-con-cancer-colorrectal-metastasico-mcrc-en-corea-del-sur 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/a-study-to-monitor-the-fruzaqla-treatment-of-adults-with-metastatic-colorectal-cancer-mcrc-in-south-korea 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05427487/estudio-de-ivx037-administrado-intratumoralmente-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05427487/study-of-intratumoral-ivx037-in-patients-with-advanced-or-metastatic-solid-tumours 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04224779/biopsias-liquidas-e-imagenologia-para-mejorar-la-atencion-oncologica 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04224779/liquid-biopsies-and-imaging-for-improved-cancer-care 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03803553/identificacion-y-tratamiento-de-la-enfermedad-micrometastasica-en-el-cancer-de-colon-en-estadio-iii 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03803553/identification-and-treatment-of-micrometastatic-disease-in-stage-iii-colon-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05057052/crioablacion-combinada-con-sintilimab-mas-regorafenib-en-metastasis-hepaticas-de-cancer-colorrectal-previamente-tratadas 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05057052/cryoablation-combined-with-sintilimab-plus-regorafenib-in-previously-treated-colorectal-cancer-liver-metastasis 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04230187/bevacizumab-mas-mfolfoxiri-como-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230187/bevacizumab-plus-mfolfoxiri-as-first-line-treatment-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06728072/adicion-de-antibioticos-al-regimen-de-tratamiento-inicial-para-el-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06728072/addition-of-antibiotics-to-upfront-treatment-regimen-for-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT01815359/icarus-quimioterapia-intraperitoneal-postoperatoria-epic-y-quimioterapia-intraperitoneal-hiperermica-hipec-tras-una-cirugia-citoreductora-optima-crs-para-neoplasias-del-apendice-colon-o-recto-con 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT01815359/icarus-post-operative-intraperitoneal-chemotherapy-epic-and-hyperthermic-intraperitoneal-chemotherapy-hipec-after-optimal-cytoreductive-surgery-crs-for-neoplasms-of-the-appendix-colon-or-rectum-with 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04673955/investigacion-en-la-practica-clinica-del-inhibidor-de-braf-encorafenib-y-el-cetuximab-como-tratamiento-de-nueva-generacion-para-el-ccrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04673955/braf-inhibitor-encorafenib-and-cetuximab-real-life-investigation-of-next-generation-crc-treatment 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07540572/un-estudio-para-investigar-la-seguridad-la-farmacocinetica-y-la-eficacia-preliminar-de-la-terapia-con-ide574-en-participantes-adultos-con-tumores-solidos-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07540572/a-study-to-investigate-the-safety-pharmacokinetics-and-preliminary-efficacy-of-ide574-therapy-in-adult-participants-with-advanced-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07543471/un-estudio-de-fase-i-multicentrico-aleatorizado-doble-ciego-y-controlado-en-paralelo-que-compara-hlx05-n-con-erbitux-r-en-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543471/a-phase-i-multicentre-randomized-double-blind-parallel-controlled-study-of-hlx05-n-vs-erbitux-r-in-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05755672/biomarcadores-durante-el-tratamiento-en-el-cancer-colorrectal-metastasico-para-mejorar-la-calidad-de-vida 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05755672/on-treatment-biomarkers-in-metastatic-colorectal-cancer-for-life 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04796818/una-exploracion-de-investigacion-imagen-por-difusion-ponderada-con-el-modelo-de-movimiento-incoherente-intravoxel-para-la-evaluacion-de-la-respuesta-al-tratamiento-de-las-metastasis-hepaticas-del 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04796818/an-investigational-scan-intravoxel-incoherent-motion-diffusion-weighted-imaging-for-the-evaluation-of-colorectal-cancer-liver-metastases-treatment-response 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/el-papel-del-pet-tc-con-18f-fdg-y-68ga-fapi-en-el-diagnostico-y-la-evaluacion-de-la-eficacia-del-cancer-colorrectal-avanzado-metastasis-peritoneal-con-o-sin-otras-metastasis 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/the-role-of-18f-fdg-and-68ga-fapi-pet-ct-in-the-diagnosis-and-the-efficacy-evaluation-of-advanced-colorectal-cancer-peritoneal-metastasis-with-without-other-metastases 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06149481/estudio-de-fase-i-ii-del-regimen-de-inmunoterapia-combinada-sx-682-vacuna-triadeno-retifanlimab-y-agonista-de-il-15-n-803-star15-para-el-cancer-colorrectal-metastasico-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06149481/phase-i-ii-study-of-the-combination-immunotherapy-regimen-sx-682-triadeno-vaccine-retifanlimab-and-il-15-agonist-n-803-star15-for-metastatic-colorectal-cancer-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05775146/radioterapia-estereotactica-ablativa-sbrt-de-metastasis-tras-el-tratamiento-neoadyuvante-para-el-cancer-colorrectal-con-metastasis-hepaticas-sincronicas 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05775146/sbrt-of-metastases-following-neo-adjuvant-treatment-for-colorectal-cancer-with-synchronous-liver-metastases 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/ensayo-de-fase-ii-abierto-y-no-aleatorizado-sobre-quimioinmunoterapia-neoadyuvante-para-el-cancer-colorrectal-no-metastasico-y-resecable-nicer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/phase-ii-open-label-trial-of-neoadjuvant-immunochemotherapy-for-resectable-non-metastatic-colon-cancer-nicer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06227728/analisis-de-la-dinamica-de-pd-l1-tmb-msi-y-ctdna-para-predecir-y-monitorizar-la-respuesta-a-la-inmunoterapia-en-el-cancer-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06227728/analysis-of-pd-l1-tmb-msi-and-ctdna-dynamics-to-predict-and-monitor-response-to-immunotherapy-in-metastatic-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabina-y-atezolizumab-para-el-cancer-colorrectal-oligo-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabine-and-atezolizumab-for-oligometastatic-crc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05501353/exploracion-de-biomarcadores-asociados-con-el-pronostico-del-cancer-colorrectal-recurrente-y-metastasico-tras-la-cirugia-mediante-metodos-multiomicos 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05501353/explore-biomarkers-associated-with-prognosis-of-recurrent-and-metastatic-crc-after-surgery-by-multi-omics-methods 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549399/terapia-neoadyuvante-inmunooncologica-dirigida-con-radioterapia-estereotactica-y-quimioterapia-para-pacientes-con-cancer-de-vejiga-de-alto-riesgo-con-pmmr-mss 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549399/scrt-chemo-targeted-immuno-neoadjuvant-therapy-for-high-risk-pmmr-mss-rc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04716257/un-estudio-prospectivo-multicentrico-y-observacional-de-pacientes-con-cancer-colorrectal-metastasico-en-ovario 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04716257/a-prospective-multi-center-real-world-study-of-ovarian-metastatic-colorectal-cancer-patients 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04485013/ttx-080-antagonista-de-hla-g-en-sujetos-con-canceres-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04485013/ttx-080-hla-g-antagonist-in-subjects-with-advanced-cancers 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04999761/estudio-de-la-plataforma-ab122 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04999761/ab122-platform-study 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07552207/comparacion-de-la-pet-rm-con-68ga-ga-ctr-fapi-y-18f-fdg-para-la-estadificacion-de-los-ganglios-linfaticos-en-el-cancer-de-recto 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07552207/comparison-of-68ga-ga-ctr-fapi-and-18f-fdg-pet-mri-for-lymph-node-staging-in-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06655142/estudio-oscar-ii-el-estudio-oncobind-sobre-la-eliminacion-de-ctc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06655142/oscar-ii-study-the-oncobind-ctc-removal-study 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/tratamiento-de-primera-linea-con-mcapox-cetuximab-frente-a-mfolfox6-cetuximab-en-pacientes-con-cmmr-no-operable-del-lado-izquierdo-con-ras-braf-tipo-salvaje-y-mss-un-estudio-multicentrico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/first-line-treatment-of-mcapox-cetuximab-vs-mfolfox6-cetuximab-for-ras-braf-wild-type-mss-unresectable-left-sided-mcrc-a-multicenter-randomized-controlled-phase-iii-study 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06938971/ensayo-clinico-aleatorizado-y-controlado-para-evaluar-los-efectos-del-ejercicio-combinado-de-resistencia-y-aerobico-en-la-calidad-de-vida-relacionada-con-la-salud-en-pacientes-que-reciben 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06938971/randomized-controlled-trial-of-the-effects-of-combined-resistance-and-aerobic-exercise-on-health-related-quality-of-life-in-patients-undergoing-first-line-chemotherapy-for-metastatic-colorectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06643793/evaluacion-del-liposoma-de-irinotecan-ii-en-combinacion-con-5-fu-lv-y-bevacizumab-para-el-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06643793/evaluation-of-irinotecan-liposome-ii-combined-with-5-fu-lv-and-bevacizumab-for-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/cetuximab-o-bevacizumab-guiados-por-ctdna-mas-trifluridina-tipiracil-en-pacientes-con-mcrc-con-ras-braf-de-tipo-salvaje 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/ctdna-guided-cetuximab-or-bevacizumab-plus-trifluridine-tipiracil-in-ras-braf-wild-type-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02945566/podemos-preservar-el-recto-mediante-una-estrategia-de-vigilancia-estrecha-o-cirugia-transanal-despues-de-la-quimio-radioterapia-en-comparacion-con-la-reseccion-mesorrectal-total-en-el-cancer-rectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02945566/can-we-save-the-rectum-by-watchful-waiting-or-transanal-surgery-following-chemo-radiotherapy-versus-total-mesorectal-excision-for-early-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07365527/sonoporacion-y-respuesta-del-microambiente-tumoral-en-metastasis-hepaticas-de-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365527/sonoporation-and-tumor-microenvironment-response-in-colorectal-liver-metastases 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05487248/un-estudio-de-los-cambios-en-el-ctdna-durante-el-tratamiento-en-pacientes-con-cancer-colorrectal-resistente-a-la-quimioterapia 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05487248/a-study-of-on-treatment-ctdna-changes-in-chemo-refractory-colorectal-cancer-patients 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06305247/un-estudio-para-evaluar-ipn01194-cuando-se-administra-solo-en-adultos-con-tumores-solidos-avanzados 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06305247/a-study-to-assess-ipn01194-when-administered-alone-in-adults-with-advanced-solid-tumours 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05056077/mejorar-la-nutricion-y-la-actividad-fisica-en-pacientes-supervivientes-de-cancer-herramientas-para-mantenerse-en-forma 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05056077/improving-nutrition-and-physical-activity-for-cancer-survivors-tools-to-be-fit 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07124858/estudio-prospectivo-multicentrico-a-nivel-nacional-para-evaluar-los-factores-pronosticos-relacionados-con-la-eficacia-del-tratamiento-con-fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07124858/prospective-national-cohort-evaluating-prognostic-factors-for-efficacy-of-fruquintinib-treatment-in-patients-with-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT00335816/radioterapia-y-fluorouracilo-con-o-sin-quimioterapia-combinada-seguido-de-cirugia-en-el-tratamiento-de-pacientes-con-cancer-de-recto-en-estadio-ii-o-estadio-iii 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT00335816/radiation-therapy-and-fluorouracil-with-or-without-combination-chemotherapy-followed-by-surgery-in-treating-patients-with-stage-ii-or-stage-iii-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381764/romance-irinotecan-mas-cetuximab-en-un-nuevo-ciclo-de-tratamiento-versus-trifluridina-tipiracil-mas-bevacizumab-en-cancer-colorrectal-metastasico-molecularmente-seleccionado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381764/romance-irinotecan-plus-cetuximab-rechallenge-versus-trifluridine-tipiracil-plus-bevacizumab-in-molecularly-selected-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06835179/radioterapia-estereotactica-ablativa-sbrt-combinada-con-capeox-bevacizumab-e-inhibidor-de-pd-1-para-el-tratamiento-del-cancer-colorrectal-metastasico-irresecable-con-mutacion-en-ras-y-de-tipo-mss 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06835179/sbrt-combined-with-capeox-bevacizumab-and-pd-1-inhibitor-for-the-treatment-of-ras-mutant-mss-type-unresectable-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06764680/quimioterapia-oral-terapia-dirigida-e-inmunoterapia-con-o-sin-radioterapia-como-terapia-de-tercera-linea-o-posterior-para-el-cancer-colorrectal-avanzado-mss-pmmr 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06764680/oral-chemotherapy-targeted-therapy-and-immunotherapy-with-without-radiotherapy-as-3rd-or-later-line-therapy-for-advanced-mss-pmmr-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06910657/idov-inmune-para-tumores-solidos-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06910657/idov-immune-for-advanced-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06195670/estudio-clinico-de-radioterapia-de-corta-duracion-seguida-de-fruquintinib-mas-sintilimab-frente-a-bevacizumab-mas-capecitabina-como-tratamiento-de-primera-linea-en-pacientes-con-mcrc-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06195670/clinical-study-of-short-course-radiotherapy-followed-by-fruquintinib-plus-sintilimab-vs-bevacizumab-plus-capecitabine-as-first-line-treatment-in-advanced-mcrc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07001085/monitorizacion-del-ctdna-en-pacientes-con-chc-y-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001085/ctdna-monitoring-in-patients-with-hcc-and-mcrc 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06528353/deteccion-mediante-biomarcadores-sanguineos-en-el-cribado-de-cpc-impulsado-por-el-vph 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06528353/blood-biomarkers-based-screening-for-hpv-driven-opc 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06008054/un-estudio-de-si-b003-bl-b01d1-si-b003-y-bl-b01d1-anticuerpo-monoclonal-anti-pd-1-en-pacientes-con-cancer-de-esofago-localmente-avanzado-o-metastasico-cancer-gastrico-cancer-colorrectal-y-otros 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008054/a-study-of-si-b003-bl-b01d1-si-b003-and-bl-b01d1-pd-1-monoclonal-antibody-in-patients-with-locally-advanced-or-metastatic-esophageal-cancer-gastric-cancer-colorectal-cancer-and-other-gastrointestinal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05700656/galunisertib-en-combinacion-con-capecitabina-en-el-tratamiento-del-cancer-colorrectal-avanzado-con-microsatelites-estables-mss 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05700656/galunisertib-combined-with-capecitabine-in-advanced-crc-with-pm 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-en-combinacion-con-sintilimab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-avanzado-excluyendo-las-metastasis-hepaticas 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-combined-with-sintilimab-as-first-line-treatment-for-advanced-non-liver-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07395063/un-estudio-clinico-sobre-el-tratamiento-del-cancer-colorrectal-metastasico-en-segunda-linea-o-posterior 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07395063/a-clinical-study-on-the-treatment-of-metastatic-colorectal-cancer-at-the-second-line-or-beyond 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05962502/cetuximab-mas-irinotecan-en-pacientes-con-cancer-colorrectal-metastasico-con-tipo-salvaje-de-neoras-en-terapia-de-tercera-linea 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05962502/cetuximab-plus-irinotecan-in-patients-with-neoras-wild-type-metastatic-colorectal-cancer-in-third-line-therapy 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02885753/oxaliplatino-sistemico-o-quimioterapia-intraarterial-combinada-con-lv5fu2-irinotecan-y-una-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-restringido-al-higado 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02885753/systemic-oxaliplatin-or-intra-arterial-chemotherapy-combined-with-lv5fu2-irinotecan-and-an-target-therapy-in-first-line-treatment-of-metastatic-colorectal-cancer-restricted-to-the-liver 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940778/biopsia-liquida-centrada-en-las-celulas-tumorales-circulantes-y-el-adn-tumoral-circulante-como-herramienta-de-medicina-de-precision-en-los-tumores-gastrointestinales 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940778/liquid-biopsy-focusing-on-circulating-tumor-cells-and-circulating-tumor-dna-as-precision-medicine-in-gastrointestinal-tumors 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06298916/64cu-lnth-1363s-en-pacientes-con-sarcoma-o-cancer-del-tracto-gastrointestinal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06298916/64cu-lnth-1363s-in-patients-with-sarcoma-or-gastrointestinal-tract-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparacion-de-la-radioterapia-abdominal-guiada-por-pet-con-68ga-fapi-combinada-con-la-terapia-estandar-de-segunda-linea-y-cadonilimab-frente-a-la-terapia-estandar-de-segunda-linea-en-el-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparing-18f-fapi-pet-guided-abdominal-radiotherapy-combined-with-second-line-standard-therapy-and-cadonilimab-versus-second-line-standard-therapy-in-colorectal-cancer-with-peritoneal-metastasis 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06412198/un-estudio-multicentrico-de-fase-1b-2-con-adagrasib-cetuximab-y-cemiplimab-para-el-cancer-colorrectal-metastasico-que-presenta-mutaciones-kras-g12c 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06412198/a-multicenter-phase-1b-2-study-of-adagrasib-cetuximab-and-cemiplimab-for-metastatic-colorectal-cancer-harboring-kras-g12c-mutations 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07585279/un-estudio-clinico-de-irinotecan-liposomal-para-la-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07585279/a-clinical-study-of-liposomal-irinotecan-for-second-line-therapy-in-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-con-metastasis-hepaticas 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-combined-with-pd-1-in-liver-metastasis-colorectal-cancer-patients 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06047015/electroforesis-irreversible-nanoknife-r-e-inmunoterapia-para-el-tratamiento-del-cancer-colorrectal-en-estadio-iv 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06047015/irreversible-electroporation-nanoknife-r-and-immunotherapy-for-the-treatment-of-stage-iv-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03715933/estudio-de-fase-i-de-inbrx-109-en-sujetos-con-tumores-solidos-avanzados-localmente-o-metastasicos-incluidos-los-sarcomas 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03715933/phase-1-study-of-inbrx-109-in-subjects-with-locally-advanced-or-metastatic-solid-tumors-including-sarcomas 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06778863/un-estudio-de-clsp-1025-en-pacientes-adultos-con-tumores-solidos-que-presentan-la-mutacion-p53-r175h 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06778863/a-study-of-clsp-1025-in-adult-patients-with-solid-tumors-that-harbor-the-p53-r175h-mutation 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02886104/comparacion-de-la-hepatectomia-y-la-ablacion-local-para-el-tratamiento-de-metastasis-hepaticas-sincronicas-y-metacronicas-resecables-del-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02886104/comparison-of-hepatectomy-and-local-ablation-for-resectable-synchronous-and-metachronous-colorectal-liver-metastasis 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07133750/pm8002-bnt327-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07133750/pm8002-bnt327-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06067620/hemicolectomia-derecha-robotica-frente-a-hemicolectomia-derecha-laparoscopica 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06067620/robotic-right-hemicolectomy-versus-laparoscopic-right-hemicolectomy 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06879873/vigilancia-guiada-por-la-enfermedad-residual-minima-en-el-adenocarcinoma-de-colon-operable-estadios-i-iii-surveillance-i 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06879873/mrd-guided-surveillance-in-operable-colon-adenocarcinoma-i-iii-surveillance-i 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06130826/activacion-de-la-respuesta-inmune-para-el-tratamiento-del-cancer-colorrectal-metastasico-irresecable-o-del-cancer-de-mama-metastasico-con-niveles-elevados-de-cea 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06130826/immune-response-activation-for-the-treatment-of-unresectable-metastatic-colorectal-cancer-or-cea-positive-metastatic-breast-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04670679/un-estudio-de-escalada-de-dosis-expansion-de-eras-601-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04670679/a-dose-escalation-expansion-study-of-eras-601-in-patients-with-advanced-or-metastatic-solid-tumors 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/mejorando-el-diagnostico-y-el-tratamiento-de-los-pacientes-con-cancer-de-recto 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/improving-diagnosis-and-treatment-for-patients-with-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06997458/biopsia-liquida-cancer-de-pulmon-y-cancer-de-colon-en-andalucia 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06997458/liquid-biopsy-lung-and-colon-cancer-in-andalucia 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07193862/estudio-piloto-de-un-microdispositivo-implantable-para-la-evaluacion-in-situ-de-la-respuesta-a-farmacos-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/pilot-study-of-an-implantable-microdevice-for-in-situ-evaluation-of-drug-response-in-patients-with-colorectal-liver-metastasis 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06566755/cadonilimab-ak104-en-combinacion-con-quimioterapia-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-mutacion-en-ras-o-con-metastasis-en-el-lado-derecho-y-con 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06566755/cadonilimab-ak104-combined-with-chemotherapy-and-bevacizumab-as-first-line-treatment-for-ras-mutated-or-right-sided-metastatic-mss-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06619886/terapia-con-celulas-t-modificadas-con-tcr-dirigido-a-tp53-r248-para-tumores-solidos-avanzados 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06619886/tp53-r248q-tcr-t-cell-therapy-for-advanced-solid-tumor 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04516681/combinacion-de-acido-ascorbico-intravenoso-y-adebrelimab-en-cancer-colorrectal-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combination-of-iv-ascorbic-acid-and-adebrelimab-in-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06621173/un-ensayo-clinico-que-evalua-la-seguridad-y-la-eficacia-del-srrna-intravenoso-hnf4-en-el-tratamiento-de-pacientes-con-crc-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06621173/a-clinical-trial-evaluating-the-safety-and-efficacy-of-intravenous-hnf4-srrna-in-treating-metastatic-crc-patients 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT02314169/nivolumab-con-o-sin-ipilimumab-en-el-tratamiento-de-pacientes-con-cancer-metastasico-del-conducto-anal-refractario 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02314169/nivolumab-with-or-without-ipilimumab-in-treating-patients-with-refractory-metastatic-anal-canal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430540/optimizando-los-itinerarios-asistenciales-para-pacientes-con-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430540/optimising-colorectal-cancer-patient-pathways 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06024837/rendimiento-de-la-tomografia-computarizada-espectral-en-pacientes-con-cancer-colorrectal-metastasico-un-estudio-multicentrico-prospectivo 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/performance-of-spectral-ct-scan-in-patients-with-metastatic-colorectal-cancer-a-prospective-multicentre-study 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959589/eficacia-y-seguridad-de-ibi351-cetuximab-en-combinacion-con-folfiri-como-tratamiento-de-primera-linea-y-de-ibi351-cetuximab-como-tratamiento-de-segunda-linea-en-el-tratamiento-del-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959589/the-efficacy-and-safety-of-ibi351-cetuximab-combined-with-folfiri-as-first-line-ibi351-cetuximab-as-second-line-in-the-treatment-of-kras-g12c-mutated-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-y-tremelimumab-con-o-sin-radioterapia-en-dosis-altas-o-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-o-cancer-de-pulmon-no-microcitico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-and-tremelimumab-with-or-without-high-or-low-dose-radiation-therapy-in-treating-patients-with-metastatic-colorectal-or-non-small-cell-lung-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07662031/tovecimig-mas-folfiri-en-segunda-linea-para-el-cancer-colorrectal-metastasico 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07662031/tovecimig-plus-folfiri-in-second-line-metastatic-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06028724/un-estudio-sobre-la-prevalencia-de-mutaciones-clinicamente-relevantes-en-tumores-solidos-caracterizados-mediante-metodos-de-secuenciacion-de-nueva-generacion-en-el-analisis-de-biopsia-liquida-popcorn 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06028724/a-study-on-the-prevalence-of-clinically-useful-mutations-in-solid-tumor-characterized-by-next-generation-sequencing-methods-on-liquid-biopsy-analysis-popcorn 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07000305/un-estudio-de-cetuximab-combinado-con-envolimab-y-mfolfox6-en-sujetos-con-cancer-colorrectal-avanzado 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07000305/a-study-of-cetuximab-combined-with-envolimab-and-mfolfox6-in-subjects-with-advanced-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07669454/un-estudio-aleatorizado-doble-ciego-controlado-con-placebo-de-grupos-paralelos-comparativo-de-fase-iii-para-evaluar-la-eficacia-y-la-seguridad-de-las-capsulas-de-nuvastatic-r-de-300-mg-en-la 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07669454/a-randomized-double-blind-placebo-controlled-parallel-group-comparative-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-nuvastatic-r-300mg-capsule-in-reducing-cancer-tumor-in-patients-with 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06885424/un-estudio-de-seguimiento-a-largo-plazo-de-los-participantes-tratados-con-productos-de-terapia-genica-tg-de-a2-biotherapeutics-a2-bio 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06885424/a-long-term-follow-up-study-of-participants-treated-with-a2-biotherapeutics-a2-bio-gene-therapy-gt-products 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07670312/evaluacion-de-xya02-en-pacientes-con-tumores-solidos-avanzados 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07670312/evaluation-of-xya02-in-patients-with-advanced-solid-tumors 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT06307925/un-estudio-de-fase-i-para-evaluar-la-seguridad-la-farmacocinetica-y-la-actividad-antitumoral-de-hc010-en-pacientes-con-tumores-solidos-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307925/a-phase-i-study-to-evaluate-the-safety-pharmacokinetics-and-antitumor-activity-of-hc010-in-patients-with-advanced-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07189871/177lu-betabart-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-inoperables-o-tumores-solidos-recurrentes-refractarios 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07189871/177lu-betabart-in-patients-with-relapsed-refractory-locally-advanced-inoperable-or-metastatic-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07204574/estudio-de-fase-1b-iia-abierto-de-escalada-y-expansion-de-dosis-para-evaluar-la-seguridad-la-tolerabilidad-y-la-eficacia-preliminar-de-la-combinacion-de-hcb101-cetuximab-bevacizumab-y-folfox-folfiri 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07204574/the-phase-1b-iia-open-label-dose-escalation-and-dose-expansion-to-evaluate-safety-tolerability-and-preliminary-efficacy-of-the-combination-of-hcb101-cetuximab-bevacizumab-and-folfox-folfiri-in 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/un-estudio-para-evaluar-el-tratamiento-de-tercera-linea-con-fruquintinib-en-combinacion-con-serplulimab-en-pacientes-con-cancer-colorrectal-metastasico-avanzado-no-limitado-al-higado-un-estudio-de 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/a-study-to-explore-the-third-line-treatment-of-fruquintinib-combined-with-serplulimab-in-advanced-non-liver-limited-metastatic-colorectal-cancer-a-single-center-phase-2-study 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446465/quimioterapia-folfox-combinada-con-fruquintinib-y-serplulimab-como-terapia-de-conversion-de-primera-linea-para-cancer-colorrectal-pmmr-mss-inicialmente-irresecable 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446465/folfox-chemotherapy-combined-with-fruquintinib-and-serplulimab-as-first-line-conversion-therapy-for-initially-unresectable-pmmr-mss-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT03755739/infusion-transarterial-intratumoral-de-inhibidores-de-puntos-de-control-mas-quimioterapia-para-la-inmunoterapia-de-tumores-solidos-avanzados 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT03755739/trans-artery-intra-tumor-infusion-of-checkpoint-inhibitors-plus-chemodrug-for-immunotherapy-of-advanced-solid-tumors 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07677579/nimble-crc-neoinmunomodulacion-antes-de-la-cirugia-en-el-cancer-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07677579/nimble-crc-neoimmunomodulation-before-leveraging-excision-in-colorectal-rectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05904665/estrategia-de-seguimiento-postoperatorio-guiada-por-la-metilacion-del-adn-tumoral-circulante-en-el-cancer-colorrectal-no-metastasico 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05904665/circulating-tumor-dna-methylation-guided-postoperative-follow-up-strategy-for-non-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT04157322/marcadores-plasmaticos-de-5hmc-como-indicador-de-metastasis-peritoneal-en-cancer-colorrectal-apendicular 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT04157322/plasma-5hmc-signatures-as-a-marker-of-colorectal-appendiceal-peritoneal-metastasis 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07150247/seguridad-y-eficacia-de-ib-folfiri-en-el-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07150247/safety-and-efficacy-of-ib-folfiri-in-braf-v600e-mutant-metastatic-colorectal-cancer 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT07453875/ldrt-quimioterapia-inmunologica-secuencial-con-nips-para-metastasis-peritoneales-de-cancer-gastrico-y-colorrectal 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT07453875/ldrt-sequential-nips-immunochemotherapy-for-peritoneal-metastasis-of-gastric-and-colorectal-cancer 2026-07-29 weekly 0.6 https://crcwarriors.org/ensayo/NCT05248581/trasplante-hepatico-de-donante-vivo-para-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-07-29 weekly 0.7 https://crcwarriors.org/ensayo/NCT05248581/living-donor-liver-transplant-for-unresectable-colorectal-liver-metastases 2026-07-29 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-07-25 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-07-25 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-07-25 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-07-25 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-07-10 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-07-10 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-07-09 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-07-09 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-07-14 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-07-14 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/letrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/letrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-07-08 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-07-08 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-06-09 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-06-09 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/pumitamig 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/pumitamig/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-07-10 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-07-10 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nw-301v 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301v/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/hrs-4642 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hrs-4642/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/itraconazole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/itraconazole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nw-301d 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301d/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-07-01 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-07-01 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/neratinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/neratinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/calderasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/calderasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selpercatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/selpercatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanzalintinib 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/zanzalintinib/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-06-04 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-06-04 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10370 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10370/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/rnk08954 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/rnk08954/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ivosidenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ivosidenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10502 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10502/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pralsetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pralsetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/s-531011 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/s-531011/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/ceralasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ceralasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/d-1553 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/d-1553/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgn1 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/sgn1/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/anastrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/anastrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/exemestane 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/exemestane/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imlunestrant 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/imlunestrant/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/azd5305 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/azd5305/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak119 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak119/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elimusertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/elimusertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entrectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entrectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/erdafitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erdafitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ssgj-612 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/ssgj-612/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fmt 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/fmt/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-20117 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20117/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/fluzoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fluzoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/capivasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/capivasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rezatapop 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapop/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/leflunomide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/leflunomide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipatasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ipatasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camizestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/camizestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dato-dxd 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dato-dxd/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rmc-4630 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-4630/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/ga-nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hf50 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hf50/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bgb-43395 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bgb-43395/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pm8002 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pm8002/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pemigatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pemigatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citrafleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citrafleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abiraterone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/abiraterone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/hsk42360 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hsk42360/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/utidelone 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/utidelone/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gh21 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gh21/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/a166 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/a166/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/avzo-021 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/avzo-021/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sph5030 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sph5030/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gemnabp 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gemnabp/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rezatapopt 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapopt/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/savolitinib 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/savolitinib/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/bms-986504 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bms-986504/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/rp2 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/rp2/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-23e73 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-23e73/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/yl-17231 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/yl-17231/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/alpelisib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alpelisib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citraflee 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citraflee/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/kqb198 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/kqb198/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/lazertinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/lazertinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vs-7375 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/vs-7375/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hmbd-001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hmbd-001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/surufatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/surufatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tazemetostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tazemetostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inca33890 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/inca33890/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ensartinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/ensartinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6291 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6291/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07799933 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07799933/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/star0602 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/star0602/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bl-m17d1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bl-m17d1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibrutinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibrutinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngr-htnf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngr-htnf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/articulo/2780/la-apigenina-7-glucosido-reprograma-el-metabolismo-tumoral-y-mejora-la-eficacia-de-la-inmunoterapia-en-el-cancer-colorrectal-a-traves-de-dlx5 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2780/apigenin-7-glucoside-reprograms-tumor-metabolism-and-enhances-immunotherapy-efficacy-in-colorectal-cancer-via-dlx5 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2769/transportador-de-glucosa-1-en-la-salud-y-la-enfermedad 2026-07-26 monthly 0.5 https://crcwarriors.org/articulo/2769/glucose-transporter-1-in-health-and-disease 2026-07-26 monthly 0.5 https://crcwarriors.org/articulo/2764/nanoplataforma-probiotica-modificada-geneticamente-para-la-terapia-del-cancer-colorrectal-mediante-ultrasonido-que-permite-la-administracion-dirigida-la-modulacion-inmune-y-la-inhibicion-de-la 2026-07-26 monthly 0.5 https://crcwarriors.org/articulo/2764/genetically-engineered-probiotic-nanoplatform-for-ultrasound-enhanced-colorectal-cancer-therapy-via-targeted-delivery-immune-modulation-and-anti-angiogenesis 2026-07-26 monthly 0.5 https://crcwarriors.org/articulo/2727/biomarcadores-multiomicos-de-la-respuesta-al-tratamiento-neoadyuvante-en-el-cancer-de-recto-una-revision-narrativa 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2727/multi-omic-biomarkers-of-neoadjuvant-treatment-response-in-rectal-cancer-a-narrative-review 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2720/terapia-neoadyuvante-total-frente-a-quimiorradioterapia-neoadyuvante-estandar-para-el-cancer-colorrectal-localmente-avanzado-una-revision-sistematica-y-metaanalisis-de-los-resultados-a-largo-plazo 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2720/total-neoadjuvant-therapy-versus-standard-neoadjuvant-chemoradiotherapy-for-locally-advanced-rectal-cancer-a-systematic-review-and-meta-analysis-of-long-term-outcomes 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2715/valor-pronostico-y-perfil-transcriptomico-espacial-de-los-patrones-de-crecimiento-histopatologicos-en-metastasis-hepaticas-sincronicas-de-cancer-colorrectal 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2715/prognostic-value-and-spatial-transcriptomic-landscape-of-histopathological-growth-patterns-in-synchronous-colorectal-liver-metastases 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2709/aplicaciones-del-aprendizaje-profundo-en-el-tratamiento-del-cancer-prediccion-base-de-investigacion-exhaustiva-para-una-revision-sistematica-y-un-metaanalisis 2026-07-17 monthly 0.5 https://crcwarriors.org/articulo/2709/deep-learning-applications-in-cancer-treatment-prediction-comprehensive-research-foundation-for-systematic-review-and-meta-analysis 2026-07-17 monthly 0.5 https://crcwarriors.org/articulo/2658/6ppdq-favorece-la-progresion-maligna-del-cancer-colorrectal-al-potenciar-la-senalizacion-de-egf-egfr 2026-07-23 monthly 0.5 https://crcwarriors.org/articulo/2658/6ppdq-promotes-the-malignant-progression-of-colorectal-cancer-via-enhancing-egf-egfr-signaling 2026-07-23 monthly 0.5 https://crcwarriors.org/articulo/2655/dos-lineas-celulares-dos-historias-caracterizacion-de-la-eficacia-diferencial-de-los-farmacos-de-molecula-pequena-cediranib-y-nu-7441-en-el-cancer-colorrectal-primario-frente-al-metastasico 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2655/a-tale-of-two-cell-lines-characterization-of-differential-efficacy-of-small-molecule-drugs-cediranib-and-nu-7441-on-primary-versus-metastatic-colorectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2639/larotrectinib-en-el-tratamiento-adyuvante-y-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-fusion-de-ntrk 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2639/larotrectinib-in-adjuvant-and-first-line-treatment-for-metastatic-ntrk-fusion-colon-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2631/evaluacion-mediante-resonancia-magnetica-con-difusion-y-secuencias-en-fase-cest-mri-del-cancer-colorrectal-localmente-avanzado-con-pmmr-para-predecir-el-estado-de-activacion-inmune-tras-la 2026-07-16 monthly 0.5 https://crcwarriors.org/articulo/2631/cest-mri-assessment-of-locally-advanced-pmmr-rectal-cancer-for-prediction-of-immune-activation-status-following-radiotherapy 2026-07-16 monthly 0.5 https://crcwarriors.org/articulo/2497/el-anticuerpo-anti-tigit-30-278-igg1-rmd-con-una-fraccion-cristalizable-fc-mejorada-amplifica-la-inmunidad-antitumoral-mediante-la-activacion-de-las-celulas-efectoras-y-presenta-una-accion-sinergica 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2497/fc-enhanced-anti-tigit-antibody-30-278-igg1-rmd-amplifies-antitumor-immunity-through-effector-cell-activation-and-synergizes-with-pd-1-blockade 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2495/descifrando-los-mecanismos-funcionales-de-eif3f-en-los-tumores-y-explorando-terapias-dirigidas 2026-07-23 monthly 0.5 https://crcwarriors.org/articulo/2495/deciphering-the-functional-mechanisms-of-eif3f-in-tumors-and-exploring-targeted-therapies 2026-07-23 monthly 0.5 https://crcwarriors.org/articulo/2420/la-cefarantina-induce-la-muerte-celular-inmunogenica-en-tumores-solidos-al-suprimir-la-expresion-de-la-poli-adp-ribosa-polimerasa-1-mediada-por-la-proteina-quinasa-c-zeta-y-presenta-una-accion 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2420/cepharanthine-triggers-immunogenic-cell-death-in-solid-tumors-by-suppressing-protein-kinase-c-zeta-mediated-poly-adp-ribose-polymerase-1-expression-and-synergizes-with-immunotherapy 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2405/eficacia-y-seguridad-comparativas-de-los-tratamientos-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-ras-tipo-salvaje-una-revision-sistematica-y-un-metaanalisis-de-red 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2405/comparative-efficacy-and-safety-of-first-line-treatments-for-ras-wild-type-metastatic-colorectal-cancer-a-systematic-review-and-network-meta-analysis 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2400/erlotinib-mas-bevacizumab-en-tumores-solidos-metastasicos-con-amplificacion-de-egfr-resultados-del-estudio-kosmos-i-ii-que-evalua-la-terapia-guiada-por-el-perfilado-molecular-en-canceres-avanzados 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2400/erlotinib-plus-bevacizumab-in-egfr-amplified-metastatic-solid-tumors-results-from-the-kosmos-i-ii-study-of-molecular-profiling-guided-therapy-in-advanced-cancers 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2393/diferencias-raciales-y-etnicas-en-los-resultados-del-cribado-del-cancer-de-prostata-en-los-estados-unidos-un-analisis-secundario-del-ensayo-sobre-el-cancer-de-prostata-pulmon-colon-y-ovario 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2393/racial-and-ethnic-differences-in-prostate-cancer-screening-outcomes-in-the-united-states-a-secondary-analysis-of-the-prostate-lung-colorectal-and-ovarian-cancer-trial 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2389/inmunoterapia-y-toma-de-decisiones-quirurgicas-en-el-cancer-colorrectal-asociado-al-sindrome-de-lynch-implicaciones-para-el-manejo-personalizado-y-la-revision-de-las-guias-clinicas 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2389/immunotherapy-and-surgical-decision-making-in-lynch-syndrome-associated-colorectal-cancer-implications-for-personalized-management-and-guideline-revision 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2380/terapia-dirigida-a-braf-en-tumores-no-melanoma-con-mutacion-braf-una-revision-sistematica-de-la-eficacia-que-es-amplia-pero-modulada-segun-el-tipo-histologico 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2380/braf-targeted-therapy-in-non-melanomatous-braf-mutant-tumours-a-systematic-review-of-broad-but-histology-modulated-efficacy 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2352/timel-la-integracion-de-aprendizaje-profundo-y-metodos-estadisticos-revela-patrones-espaciales-del-estroma-y-del-sistema-inmunitario-en-el-cancer-colorrectal-agresivo 2026-07-17 monthly 0.5 https://crcwarriors.org/articulo/2352/timel-deep-learning-statistical-integration-reveals-spatial-stromal-and-immune-signatures-of-aggressive-colon-cancer 2026-07-17 monthly 0.5 https://crcwarriors.org/articulo/2337/impacto-de-la-certificacion-del-oncologo-medico-en-los-resultados-de-supervivencia-en-el-cancer-colorrectal-metastasico-evidencia-del-estudio-observacional-scrum-japan-monstar-screen 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2337/impact-of-medical-oncologist-certification-on-survival-outcomes-in-metastatic-colorectal-cancer-evidence-from-the-scrum-japan-monstar-screen-observational-study 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2286/secuenciacion-rapida-de-proxima-generacion-in-situ-an-alternative-to-single-gene-and-send-out-testing-in-non-small-cell-lung-cancer-and-colorectal-cancer-in-a-community-pathology-laboratory-setting 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2286/rapid-on-site-next-generation-sequencing-an-alternative-to-single-gene-and-send-out-testing-in-non-small-cell-lung-cancer-and-colorectal-cancer-in-a-community-pathology-laboratory-setting 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2250/caracterizacion-espectroscopica-raman-de-los-cambios-proteicos-inducidos-por-el-5-fluorouracilo-en-celulas-de-cancer-de-colon 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2250/raman-spectroscopic-characterization-of-protein-changes-induced-by-5-fluorouracil-in-colon-cancer-cells 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2243/sotorasib-en-combinacion-con-3-metiladenina-para-el-tratamiento-del-cancer-de-pancreas-con-mutacion-kras-g12c-y-sus-mecanismos-subyacentes 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2243/sotorasib-combined-with-3-methyladenine-for-the-treatment-of-kras-g12c-mutant-pancreatic-cancer-and-its-underlying-mechanisms 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2212/metastasis-hepaticas-de-cancer-colorrectal-estrategias-de-imagen-para-el-diagnostico-la-planificacion-del-tratamiento-local-y-la-evaluacion-de-la-respuesta-al-tratamiento-sistemico 2026-07-17 monthly 0.5 https://crcwarriors.org/articulo/2212/colorectal-liver-metastases-imaging-strategies-for-diagnosis-local-treatment-planning-and-systemic-treatment-response 2026-07-17 monthly 0.5 https://crcwarriors.org/articulo/2155/eficacia-de-la-dieta-mediterranea-para-la-prevencion-primaria-de-enfermedades-oncologicas-una-revision-sistematica-y-metaanalisis-que-se-incluye-en-las-guias-nacionales-italianas-la-dieta-mediterranea 2026-07-16 monthly 0.5 https://crcwarriors.org/articulo/2155/efficacy-of-mediterranean-diet-for-the-primary-prevention-of-oncological-diseases-a-systematic-review-and-meta-analysis-featured-in-the-italian-national-guidelines-la-dieta-mediterranea 2026-07-16 monthly 0.5 https://crcwarriors.org/articulo/2096/descifrando-la-heterogeneidad-de-las-celulas-del-cancer-colorrectal-identificacion-de-biomarcadores-y-subpoblaciones-celulares-impulsoras-de-la-enfermedad-mediante-scissor-y-cibersortx-en-el-analisis 2026-07-11 monthly 0.5 https://crcwarriors.org/articulo/2096/unveiling-colorectal-cancer-cell-heterogeneity-identification-of-biomarkers-and-disease-driving-cell-subpopulations-through-scissor-and-cibersortx-on-integrated-transcriptomic-profiling 2026-07-11 monthly 0.5 https://crcwarriors.org/articulo/2095/el-aprendizaje-profundo-consciente-de-firmas-revela-distintos-programas-de-genes-conductores-y-procesos-mutacionales-en-glioblastoma-y-adenocarcinoma-de-colon 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2095/signature-aware-deep-learning-reveals-distinct-driver-gene-programs-and-mutational-processes-in-glioblastoma-and-colon-adenocarcinoma 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/1498/una-plataforma-nano-basada-en-manganeso-que-aprovecha-los-efectos-quimiodynammaticos-y-adjutivos-para-la-vacunacion-in-situ-contra-el-cancer-colorrectal 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/1498/a-manganese-based-nanoplatform-leveraging-chemodynamic-and-adjuvant-effects-for-in-situ-vaccination-against-colorectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/1290/entendimiento-actual-y-manejo-de-la-metastasis-cerebral-del-cancer-colorrectal-una-revision 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/1290/current-understanding-and-management-of-brain-metastasis-from-colorectal-cancer-a-review 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2804/affinity-maturation-and-characterization-of-the-novel-monoclonal-antibody-mab-pb-223-targeting-cancer-specific-o-glycans-terminating-with-2-6-sialic-acids 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2803/comparing-the-effectiveness-and-safety-of-different-third-line-management-options-for-patients-with-metastatic-colorectal-cancer-a-systematic-review-and-reconstructed-individual-patient-data-meta 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2802/invasive-front-and-peritumoral-prognostic-factors-in-colorectal-cancer-current-perspectives-and-future-considerations 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2801/single-cell-profiling-identifies-a-ccr2-neutrophil-like-population-associated-with-colorectal-cancer-liver-metastasis-in-a-murine-model 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2800/rechallenge-therapy-new-dimensions-in-cancer-therapy 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2799/single-cell-and-spatial-transcriptomic-landscapes-reveal-pigt-as-a-pivotal-regulator-of-immunometabolic-remodeling-in-colorectal-cancer-liver-metastasis 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2798/superar-la-resistencia-a-los-tratamientos-anti-egfr-mecanismos-de-resistencia-al-cetuximab-y-al-panitumumab-y-nuevas-estrategias-de-combinacion 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2798/overcoming-resistance-to-anti-egfr-therapies-mechanisms-of-cetuximab-and-panitumumab-resistance-and-emerging-combination-strategies 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2797/immune-cytolytic-activity-correlates-with-tumor-microenvironmental-aberrations-in-colorectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2796/female-oncofertility-in-colorectal-cancer-reproductive-uncertainties-and-potential-benefits-of-immunotherapy 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2795/el-estado-de-p53-y-p21-influye-en-la-respuesta-celular-a-la-metformina-en-las-celulas-de-cancer-colorrectal-hct116-con-mutacion-en-el-gen-kras 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2795/p53-and-p21-status-influences-cellular-response-to-metformin-in-kras-mutant-hct116-colorectal-cancer-cells 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2793/molecular-plasticity-of-lama3-across-the-disease-spectrum-pathogenic-mechanisms-and-clinical-translation 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2792/analysis-on-the-incidence-and-perioperative-outcomes-of-immune-related-adverse-events-in-preoperative-immunotherapy-for-colorectal-cancer-based-on-multicenter-real-world-data 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2791/informe-de-la-27-a-conferencia-anual-de-consenso-sobre-el-cancer-gastrointestinal-del-oeste-de-canada-dedicada-al-cancer-colorrectal-celebrada-en-calgary-alberta-los-dias-26-y-27-de-septiembre-de 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2791/report-from-the-27th-annual-western-canadian-gastrointestinal-cancer-consensus-conference-on-colorectal-cancer-calgary-alberta-26-27-september-2025-advances-in-colon-and-rectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2790/sobreexpresion-amplificacion-de-her2-en-el-cancer-colorrectal-la-heterogeneidad-espacial-intratumoral-como-factor-clave-de-la-discordancia-en-la-deteccion-y-la-respuesta-al-tratamiento 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2790/her2-overexpression-amplification-in-colorectal-cancer-spatial-intratumoral-heterogeneity-as-a-key-determinant-of-detection-discordance-and-therapy-response 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2789/avances-recientes-en-la-investigacion-clinica-y-de-biologia-molecular-sobre-las-lesiones-serriladas-rectales 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2789/recent-progress-in-clinical-and-molecular-biological-research-in-rectal-serrated-lesions 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2784/dirigirse-a-las-vias-moleculares-y-geneticas-que-impulsan-la-tumorigenesis-para-lograr-una-terapia-de-precision-en-el-cancer-colorrectal 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2784/targeting-molecular-and-genetic-pathways-driving-tumorigenesis-for-precision-therapy-in-colorectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2783/dependencia-de-la-enzima-tipo-furina-en-el-cancer-colorrectal-con-mutacion-en-kras-como-diana-para-estrategias-de-tratamiento-personalizadas 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2783/furin-like-enzyme-dependency-in-kras-mutant-colorectal-cancer-as-a-target-for-personalized-treatment-strategies 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2781/los-efectos-inmunogenicos-de-la-hipertermia-en-un-modelo-experimental-de-metastasis-peritoneales-del-cancer-colorrectal-aumentan-la-susceptibilidad-tumoral-a-la-inmunoterapia 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2781/immunogenic-effects-of-hyperthermia-in-an-experimental-model-of-peritoneal-metastases-of-colorectal-cancer-enhance-tumor-susceptibility-to-immunotherapy 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2779/impacto-en-la-supervivencia-de-los-eventos-adversos-graves-relacionados-con-la-inmunoterapia-en-los-canceres-digestivos-con-deficiencia-en-la-reparacion-del-desajuste-y-alta-inestabilidad-de 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2779/impact-on-survival-of-severe-immuno-related-adverse-events-in-deficient-mismatch-repair-microsatellite-instable-high-digestive-cancers-treated-with-immunotherapy 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2774/las-celulas-t-derivadas-de-ipsc-alogenicas-demuestran-eficacia-antitumoral-frente-a-tejidos-derivados-de-pacientes 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2774/allogeneic-ipsc-derived-t-cells-demonstrate-antitumor-efficacy-against-patient-derived-tissues 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2773/un-nuevo-anticuerpo-monoclonal-anti-caderina-17-ca-17-mab-5-para-multiples-aplicaciones 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2773/a-novel-anti-cadherin-17-monoclonal-antibody-ca-17-mab-5-for-multiple-applications 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2772/bifidobacterium-probiotico-modificado-geneticamente-para-la-terapia-dirigida-al-tumor-en-el-cancer-de-pancreas 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2772/engineered-probiotic-bifidobacterium-for-tumor-targeted-pancreatic-cancer-therapy 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2771/inmunoterapia-en-el-cancer-colorrectal-asociado-a-la-deficiencia-constitucional-del-sistema-de-reparacion-de-errores-de-emparejamiento-cmmrd-en-pacientes-pediatricos-informe-de-un-caso-de-una 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2771/immunotherapy-in-pediatric-constitutional-mismatch-repair-deficiency-cmmrd-associated-colorectal-cancer-report-of-a-rare-variant-and-recommendations-for-screening 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2770/terapia-neoadyuvante-total-basada-en-radioterapia-de-corta-duracion-mas-tislelizumab-para-el-cancer-colorrectal-localmente-avanzado-neo-star-resultados-preliminares-de-un-ensayo-aleatorizado-de-fase 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2770/short-course-radiotherapy-based-total-neoadjuvant-therapy-plus-tislelizumab-for-locally-advanced-rectal-cancer-neo-star-early-outcomes-of-a-randomized-phase-ii-trial 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2768/copanlisib-en-combinacion-con-nivolumab-para-el-tratamiento-del-cancer-colorrectal-con-microsatelites-estables-un-ensayo-de-fase-1-2 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2768/copanlisib-in-combination-with-nivolumab-formicrosatellite-stable-colorectal-cancer-a-phase-1-2-trial 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2767/dhodh-es-un-objetivo-sintal-letal-en-el-cancer-colorrectal-con-mutacion-en-pik3ca 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2767/dhodh-is-a-synthetic-lethal-target-in-pik3ca-mutant-colorectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2766/panorama-genomico-y-molecular-del-cancer-colorrectal-de-inicio-temprano-nuevos-conocimientos-e-implicaciones-clinicas-una-revision-sistematica 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2766/genomic-and-molecular-landscape-of-early-onset-colorectal-cancer-emerging-insights-and-clinical-implications-a-systematic-review 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2765/remodelacion-inmune-sistemica-tras-la-reseccion-curativa-r0-de-metastasis-hepaticas-de-cancer-colorrectal 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2765/systemic-immune-remodeling-following-curative-r0-resection-of-colorectal-liver-metastases 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2763/familia-de-transportadores-de-solutos-6-miembro-14-slc6a14-expresion-funcion-regulacion-e-impacto-en-la-progresion-tumoral 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2763/solute-carrier-family-6-member-14-slc6a14-expression-function-regulation-and-impact-on-tumor-progression 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2762/sirexatamab-en-combinacion-con-bevacizumab-y-quimioterapia-como-terapia-de-segunda-linea-para-el-adenocarcinoma-colorrectal-avanzado-el-ensayo-de-fase-ii-defiance 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2762/sirexatamab-in-combination-with-bevacizumab-and-chemotherapy-as-second-line-therapy-for-advanced-colorectal-adenocarcinoma-the-phase-ii-defiance-trial 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2761/resultados-de-supervivencia-y-factores-pronosticos-en-pacientes-con-cancer-colorrectal-metastasico-tratados-en-primera-linea-con-mfolfoxiri-mas-bevacizumab-un-estudio-observacional-en-vietnam 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2761/survival-outcomes-and-prognostic-factors-in-patients-with-metastatic-colorectal-cancer-treated-first-line-mfolfoxiri-plus-bevacizumab-a-real-world-study-in-vietnam 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2760/caracteristicas-de-la-microbiota-intestinal-en-el-cancer-colorrectal-con-diferentes-estados-de-inestabilidad-de-microsatelites 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2760/the-characteristics-of-gut-microbiota-in-colorectal-cancer-with-different-microsatellite-states 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2759/nueva-estrategia-de-tratamiento-y-lineas-de-investigacion-futuras-para-el-cancer-con-mutacion-en-el-gen-braf 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2759/new-treatment-strategy-and-future-research-direction-for-braf-mutated-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2758/la-inhibicion-de-kras-g12d-reprograma-el-microambiente-inmunosupresor-inducido-por-el-tumor-y-potencia-la-inmunidad-antitumoral-mediada-por-las-celulas-nk 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2758/kras-g12d-inhibition-reprograms-the-tumor-induced-immunosuppressive-environment-and-enhances-nk-cell-mediated-antitumor-immunity 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2757/el-potencial-terapeutico-de-los-conjugados-anticuerpo-farmaco-en-el-cancer-colorrectal-avanzado-una-revision-sistematica-y-metaanalisis 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2757/the-therapeutic-potential-of-antibody-drug-conjugates-in-advanced-colorectal-cancer-a-systematic-review-and-meta-analysis 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2756/revision-sistematica-y-comparacion-indirecta-ajustada-de-los-inhibidores-de-los-puntos-de-control-inmunitario-en-primera-linea-para-el-cancer-colorrectal-metastasico 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2756/systematic-review-and-adjusted-indirect-comparison-of-first-line-immune-checkpoint-inhibitors-in-metastatic-colorectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2755/un-dihidrofenantreno-derivado-de-pholidota-chinensis-actua-como-un-componente-bioactivo-que-induce-la-ferroptosis-mediada-por-gpx4-en-el-cancer-colorrectal 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2755/a-pholidota-chinensis-derived-dihydrophenanthrene-acts-as-a-bioactive-constituent-to-trigger-gpx4-mediated-ferroptosis-in-colorectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2753/vactosertib-mas-pembrolizumab-en-pacientes-con-cancer-colorrectal-o-gastrico-metastasico-con-inestabilidad-microsatelital-no-alta-un-estudio-multicentrico-de-fase-ib-iia 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2753/vactosertib-plus-pembrolizumab-in-patients-with-non-microsatellite-instability-high-metastatic-colorectal-or-gastric-cancer-a-multicenter-phase-ib-iia-study 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2752/desde-el-laboratorio-hasta-la-practica-clinica-avanzando-en-nuestra-comprension-de-la-radioresistencia-en-el-cancer-de-recto 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2752/from-bench-to-bedside-advancing-our-understanding-of-radioresistance-in-rectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2751/evaluacion-in-vitro-e-in-silico-del-potencial-antitumoral-del-extracto-etanolico-de-las-semillas-de-bryonia-laciniosa-contra-el-cancer-colorrectal-y-el-cancer-hepatocelular 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2751/in-vitro-and-in-silico-evaluation-of-the-anticancer-potential-of-ethanolic-seed-extract-of-bryonia-laciniosa-against-colorectal-and-hepatocellular-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2750/el-contexto-tisular-determina-diferentes-resultados-premalignos-en-un-modelo-transgenico-de-raton-pik3ca-mutante-hpv16-e6-e7 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2750/tissue-context-shapes-distinct-premalignant-outcomes-in-an-hpv16-e6-e7-mutant-pik3ca-transgenic-mouse-model 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2749/conjugados-anticuerpo-farmaco-en-el-cancer-colorrectal-avances-desafios-y-perspectivas 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2749/antibody-drug-conjugates-in-colorectal-cancer-advances-challenges-and-prospectives 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2745/aspirina-como-terapia-adyuvante-para-el-cancer-colorrectal-con-tumores-con-mutacion-en-pik3ca-y-sobreexpresion-de-cox-2-el-estudio-de-investigacion-traslacional-ascolt-y-metaanalisis 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2745/adjuvant-aspirin-for-colorectal-cancer-with-pik3ca-mutated-and-cox-2-overexpressed-tumours-the-ascolt-translational-research-study-and-meta-analysis 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2744/eficacia-y-seguridad-a-corto-plazo-de-la-inmunoterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-del-desajuste 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2744/short-term-efficacy-and-safety-of-neoadjuvant-immunotherapy-for-locally-advanced-colon-cancer-with-deficient-mismatch-repair 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2743/cancer-colorrectal-metastasico-diagnosticado-antes-de-los-35-anos-un-subgrupo-distinto-de-enfermedad-de-inicio-temprano 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2743/metastatic-colorectal-cancer-diagnosed-before-age-35-a-distinct-subset-of-early-onset-disease 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2742/relevancia-pronostica-de-los-margenes-quirurgicos-segun-el-estado-de-kras-y-braf-en-las-metastasis-hepaticas-del-cancer-colorrectal-grupo-colaborativo-braf-kras-livermet 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2742/prognostic-relevance-of-surgical-margins-according-to-kras-and-braf-status-in-colorectal-liver-metastases-braf-kras-livermet-collaborative-group 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2739/tratamiento-del-cancer-de-recto-localizado-en-los-paises-nordicos-comparacion-de-las-guias-nordicas-con-las-guias-holandesas-de-la-esmo-y-de-la-nccn 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2739/treatment-of-localized-rectal-cancer-in-the-nordic-countries-comparison-of-nordic-to-dutch-esmo-and-nccn-guidelines 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2738/patrones-de-progresion-y-supervivencia-en-pacientes-con-cancer-colorrectal-metastasico-dmmr-msi-h-tratados-con-inmunoterapia 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2738/patterns-of-progression-and-survival-in-patients-with-mismatch-repair-deficient-microsatellite-instability-high-metastatic-colorectal-cancer-treated-with-immunotherapy 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2737/primer-caso-descrito-de-mutaciones-duales-de-resistencia-kras-y96c-y96s-detectadas-mediante-biopsia-liquida-en-un-cancer-colorrectal-metastasico-con-mutacion-kras-g12c 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2737/first-report-of-dual-kras-y96c-y96s-resistance-mutations-detected-by-liquid-biopsy-in-kras-g12c-mutant-metastatic-colorectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2736/inmunoterapia-de-primera-linea-frente-a-quimioterapia-en-el-cancer-colorrectal-metastasico-con-msi-h-dmmr-una-revision-sistematica-y-un-metaanalisis-de-estudios-de-fase-iii 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2736/first-line-immunotherapy-versus-chemotherapy-in-msi-h-dmmr-metastatic-colorectal-cancer-a-systematic-review-and-meta-analysis-of-phase-iii-studies 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2732/caracteristicas-tumorales-y-factores-predictivos-de-supervivencia-en-pacientes-con-cancer-colorrectal-experiencia-en-un-unico-centro-en-el-libano 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2732/tumor-characteristics-and-survival-predictors-in-patients-with-colorectal-cancer-a-lebanese-single-center-experience 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2723/evolucion-de-la-resistencia-a-la-inmunoterapia-mediada-por-macrofagos-de-la-cavidad-spp1-en-la-metastasis-peritoneal-del-cancer-colorrectal 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2723/evolution-of-spp1-cavity-macrophage-mediated-immunotherapy-resistance-in-peritoneal-metastasis-of-colorectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2722/estudio-de-fase-i-de-escalada-de-dosis-que-combina-la-quimioembolizacion-con-microesferas-de-irinotecan-y-la-radioembolizacion-con-microesferas-de-vidrio-de-itrio-90-en-metastasis-hepaticas-de-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2722/phase-i-dose-escalation-study-combining-irinotecan-loaded-drug-eluting-bead-chemoembolization-with-yttrium-90-glass-microspheres-radioembolization-in-colorectal-liver-metastases-debir-90-y 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2721/la-terapia-con-celulas-car-t-dirigidas-contra-gcc-no-protegidas-demuestra-una-eficacia-significativa-en-pacientes-con-cancer-colorrectal-avanzado 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2721/non-armored-gcc-targeting-car-t-cell-therapy-demonstrates-significant-efficacy-in-patients-with-advanced-colorectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2719/prediccion-temprana-de-la-enfermedad-residual-minima-en-el-cancer-colorrectal-mediante-el-analisis-del-estado-de-metilacion-de-septin9-en-el-adn-tumoral-circulante 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2719/early-prediction-of-minimal-residual-disease-in-colorectal-cancer-via-septin9-methylation-status-in-circulating-tumor-dna 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2718/desde-la-fermentacion-hasta-los-farmabioticos-ingenieria-de-lactobacillus-derivado-del-kefir-para-una-inmunoterapia-intratumoral-dirigida-en-el-cancer-colorrectal 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2718/from-fermentation-to-pharmabiotics-engineering-kefir-derived-lactobacillus-for-targeted-intratumoral-immunotherapy-in-colorectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2717/dirigirse-al-ecosistema-espacial-metabolico-inmune-en-las-metastasis-hepaticas-del-cancer-colorrectal-estrategias-farmacologicas-y-el-paradigma-de-interrumpir-normalizar-restablecer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2717/targeting-the-spatial-metabolic-immune-ecosystem-in-colorectal-cancer-liver-metastasis-pharmacological-strategies-and-the-break-normalize-reset-paradigm 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2714/el-adn-tumoral-circulante-para-predecir-el-riesgo-de-tromboembolia-venosa-en-el-cancer-de-recto-localmente-avanzado 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2714/circulating-tumor-dna-to-predict-the-risk-of-venous-thromboembolism-in-locally-advanced-rectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2710/quimiocirugia-neoadyuvante-con-dosis-escaladas-frente-a-la-quimiocirugia-neoadyuvante-estandar-para-el-cancer-colorrectal-localmente-avanzado-resultados-a-9-anos-de-un-ensayo-aleatorizado-de-fase-2 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2710/dose-escalated-versus-standard-neoadjuvant-chemoradiotherapy-for-locally-advanced-rectal-cancer-9-year-results-of-a-randomized-phase-2-trial 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2708/alteraciones-del-genoma-mitocondrial-en-el-cancer-desde-mutaciones-y-epigenetica-hasta-terapias-dirigidas 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2708/mitochondrial-genome-alterations-in-cancer-from-mutations-and-epigenetics-to-targeted-therapiesack 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2707/imagenes-multimodales-y-caracterizacion-tisular-mediante-ecografia-mejorada-con-inteligencia-artificial-para-predecir-la-eficacia-de-la-inmunoterapia-en-el-cancer-de-recto 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2707/artificial-intelligence-enhanced-ultrasound-multimodal-imaging-and-tissue-characterization-for-predicting-immunotherapy-efficacy-in-rectal-cancer 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2705/oncologia-de-precision-de-ultima-generacion-en-el-cancer-colorrectal-con-estabilidad-en-los-microsatelites-enfoque-integrado-que-va-mas-alla-de-ras-y-raf 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2705/next-generation-precision-oncology-in-microsatellite-stable-colorectal-cancer-integrated-targeting-beyond-ras-and-raf 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2704/inhibidores-de-los-puntos-de-control-inmunitario-en-el-cancer-colorrectal-dmmr-msi-h-justificacion-avances-y-perspectivas 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2704/immune-checkpoint-inhibitors-in-dmmr-msi-h-colorectal-cancer-rationale-progress-and-prospects 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2703/impacto-pronostico-de-la-diseminacion-a-traves-de-los-espacios-aereos-y-su-asociacion-con-la-mutacion-kras-y-los-factores-histopatologicos-en-metastasis-pulmonares-de-cancer-colorrectal-resecadas 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2703/prognostic-impact-of-spread-through-air-spaces-and-its-association-with-kras-mutation-and-histopathologic-factors-in-resected-colorectal-lung-metastases 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2702/respuesta-clinica-completa-a-serplulimab-mas-bevacizumab-y-quimioterapia-en-adenocarcinoma-sigmoide-metastasico-mss-kras-mutado-informe-de-un-caso-y-revision-de-la-literatura 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2702/clinical-complete-response-to-serplulimab-plus-bevacizumab-and-chemotherapy-in-mss-kras-mutant-metastatic-sigmoid-colon-adenocarcinoma-a-case-report-and-literature-review 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2700/el-kras-mutado-suprime-la-deteccion-del-adn-al-remodelar-la-tension-de-la-membrana-para-eliminar-el-adn-tumoral-extracelular 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2700/mutant-kras-suppresses-dna-sensing-by-remodeling-membrane-tension-to-clear-extracellular-tumor-dna 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2699/trasplante-de-higado-de-donante-fallecido-y-supervivencia-postoperatoria-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal-un-estudio-multicentrico-retrospectivo 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2699/deceased-donor-liver-transplantation-and-postoperative-survival-in-patients-with-unresectable-colorectal-liver-metastases-a-retrospective-multicenter-study 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2698/los-carcinomas-colorectales-enteroblasticos-y-hepatoides-son-canceres-agresivos-con-un-inmunofenotipo-distintivo-mientras-que-el-carcinoma-de-celulas-claras-parece-representar-una-transformacion-de 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2698/enteroblastic-and-hepatoid-colorectal-carcinomas-are-aggressive-cancers-with-a-distinctive-immunophenotype-while-clear-cell-carcinoma-appears-to-represent-clear-cell-change-in-conventional-colorectal 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2692/variabilidad-genomica-de-la-linea-celular-hct116-identificada-mediante-secuenciacion-con-oxford-nanopore 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2692/genomic-variability-of-the-hct116-cell-line-identified-using-oxford-nanopore-sequencing 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2690/factores-pronosticos-y-predictivos-criticos-en-las-metastasis-hepaticas-del-cancer-colorrectal-un-analisis-exhaustivo-de-la-bibliografia-existente-y-perspectivas-de-futuro 2026-07-29 monthly 0.5 https://crcwarriors.org/articulo/2690/critical-prognostic-and-predictive-factors-in-colorectal-liver-metastasis-a-thorough-analysis-of-existing-literature-and-future-outlook 2026-07-29 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nuevas-funcionalidades-en-el-buscador-de-ensayos-clinicos-mapa-interactivo-filtros-avanzados-y-mas 2026-07-23 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nueva-experiencia-de-noticias-cientificas-ia-personalizada-traduccion-en-tiempo-real-y-mucho-mas 2026-07-21 monthly 0.5 https://crcwarriors.org/news-detail.php?id=lanzamos-la-beta-de-crc-warriors-buscamos-testers 2026-07-20 monthly 0.5 https://crcwarriors.org/news-detail.php?id=glosario-de-farmacos-2-0-mas-inteligente-mas-completo-mas-potente 2026-07-28 monthly 0.5 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-07-01 monthly 0.4